US20240027438A1 - Novel thyroid peroxidase autoantibody immunoassay - Google Patents
Novel thyroid peroxidase autoantibody immunoassay Download PDFInfo
- Publication number
- US20240027438A1 US20240027438A1 US18/473,163 US202318473163A US2024027438A1 US 20240027438 A1 US20240027438 A1 US 20240027438A1 US 202318473163 A US202318473163 A US 202318473163A US 2024027438 A1 US2024027438 A1 US 2024027438A1
- Authority
- US
- United States
- Prior art keywords
- rtpo
- antibody
- solid support
- tpo
- labeled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010036012 Iodide peroxidase Proteins 0.000 title claims abstract description 27
- 102000014267 Thyroid peroxidases Human genes 0.000 title claims abstract description 27
- 238000003018 immunoassay Methods 0.000 title abstract description 48
- 239000007787 solid Substances 0.000 claims abstract description 128
- 239000012472 biological sample Substances 0.000 claims abstract description 80
- 241000282567 Macaca fascicularis Species 0.000 claims abstract description 67
- 230000003208 anti-thyroid effect Effects 0.000 claims abstract description 36
- 229940043671 antithyroid preparations Drugs 0.000 claims abstract description 36
- 102000003992 Peroxidases Human genes 0.000 claims abstract description 35
- 108040007629 peroxidase activity proteins Proteins 0.000 claims abstract description 35
- 208000024799 Thyroid disease Diseases 0.000 claims abstract description 26
- 208000021510 thyroid gland disease Diseases 0.000 claims abstract description 24
- 238000000034 method Methods 0.000 claims description 82
- RXNXLAHQOVLMIE-UHFFFAOYSA-N phenyl 10-methylacridin-10-ium-9-carboxylate Chemical compound C12=CC=CC=C2[N+](C)=C2C=CC=CC2=C1C(=O)OC1=CC=CC=C1 RXNXLAHQOVLMIE-UHFFFAOYSA-N 0.000 claims description 21
- 239000011324 bead Substances 0.000 claims description 18
- 150000001875 compounds Chemical class 0.000 claims description 14
- 239000011159 matrix material Substances 0.000 claims description 12
- 102000004190 Enzymes Human genes 0.000 claims description 10
- 108090000790 Enzymes Proteins 0.000 claims description 10
- 239000007850 fluorescent dye Substances 0.000 claims description 7
- 230000002285 radioactive effect Effects 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 38
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 34
- 239000002245 particle Substances 0.000 description 28
- 239000000523 sample Substances 0.000 description 21
- 239000006249 magnetic particle Substances 0.000 description 20
- 239000004816 latex Substances 0.000 description 19
- 229920000126 latex Polymers 0.000 description 19
- 239000011780 sodium chloride Substances 0.000 description 19
- 238000003556 assay Methods 0.000 description 18
- 239000000427 antigen Substances 0.000 description 17
- 102000036639 antigens Human genes 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 17
- 230000005764 inhibitory process Effects 0.000 description 17
- 239000011541 reaction mixture Substances 0.000 description 17
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 16
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 16
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 16
- -1 iodide ions Chemical class 0.000 description 16
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 16
- 239000008363 phosphate buffer Substances 0.000 description 16
- 229920001992 poloxamer 407 Polymers 0.000 description 16
- 239000000600 sorbitol Substances 0.000 description 16
- 125000003396 thiol group Chemical group [H]S* 0.000 description 16
- 238000006206 glycosylation reaction Methods 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 229940098773 bovine serum albumin Drugs 0.000 description 13
- 230000005291 magnetic effect Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 229910001868 water Inorganic materials 0.000 description 12
- 108010090804 Streptavidin Proteins 0.000 description 11
- 230000013595 glycosylation Effects 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 10
- 230000005298 paramagnetic effect Effects 0.000 description 10
- 239000012470 diluted sample Substances 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 8
- 229920002678 cellulose Polymers 0.000 description 8
- 239000001913 cellulose Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 230000008878 coupling Effects 0.000 description 7
- 238000010168 coupling process Methods 0.000 description 7
- 238000005859 coupling reaction Methods 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 239000000020 Nitrocellulose Substances 0.000 description 6
- 238000002820 assay format Methods 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 229920001220 nitrocellulos Polymers 0.000 description 6
- 238000001542 size-exclusion chromatography Methods 0.000 description 6
- FQQREHKSHAYSMG-UHFFFAOYSA-N 1,2-dimethylacridine Chemical compound C1=CC=CC2=CC3=C(C)C(C)=CC=C3N=C21 FQQREHKSHAYSMG-UHFFFAOYSA-N 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 229920004439 Aclar® Polymers 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
- 239000005977 Ethylene Substances 0.000 description 4
- 108010015776 Glucose oxidase Proteins 0.000 description 4
- 239000004366 Glucose oxidase Substances 0.000 description 4
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000022811 deglycosylation Effects 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 239000011152 fibreglass Substances 0.000 description 4
- 238000005194 fractionation Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 229940116332 glucose oxidase Drugs 0.000 description 4
- 235000019420 glucose oxidase Nutrition 0.000 description 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 4
- 238000007885 magnetic separation Methods 0.000 description 4
- 239000013610 patient sample Substances 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 210000001236 prokaryotic cell Anatomy 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000006862 quantum yield reaction Methods 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 108010006232 Neuraminidase Proteins 0.000 description 3
- 102000005348 Neuraminidase Human genes 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 239000012888 bovine serum Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000001685 thyroid gland Anatomy 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 208000023328 Basedow disease Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- 101000799461 Homo sapiens Thrombopoietin Proteins 0.000 description 2
- 101000694103 Homo sapiens Thyroid peroxidase Proteins 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 239000012505 Superdex™ Substances 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-O acridine;hydron Chemical compound C1=CC=CC2=CC3=CC=CC=C3[NH+]=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-O 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 102000053400 human TPO Human genes 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000001155 isoelectric focusing Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 2
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- UVGHPGOONBRLCX-NJSLBKSFSA-N (2,5-dioxopyrrolidin-1-yl) 6-[5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]hexanoate Chemical compound C([C@H]1[C@H]2NC(=O)N[C@H]2CS1)CCCC(=O)NCCCCCC(=O)ON1C(=O)CCC1=O UVGHPGOONBRLCX-NJSLBKSFSA-N 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
- 101001123859 Homo sapiens Sialidase-1 Proteins 0.000 description 1
- 101001123851 Homo sapiens Sialidase-2 Proteins 0.000 description 1
- 101000878457 Macrocallista nimbosa FMRFamide Proteins 0.000 description 1
- 101710141452 Major surface glycoprotein G Proteins 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 102000000447 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Human genes 0.000 description 1
- 108010055817 Peptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine Amidase Proteins 0.000 description 1
- 101710165315 Sialidase A Proteins 0.000 description 1
- 102100028760 Sialidase-1 Human genes 0.000 description 1
- 102100028755 Sialidase-2 Human genes 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000010927 atrophic thyroiditis Diseases 0.000 description 1
- 125000000656 azaniumyl group Chemical group [H][N+]([H])([H])[*] 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 102000021178 chitin binding proteins Human genes 0.000 description 1
- 108091011157 chitin binding proteins Proteins 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- LGQLOGILCSXPEA-UHFFFAOYSA-L nickel sulfate Chemical compound [Ni+2].[O-]S([O-])(=O)=O LGQLOGILCSXPEA-UHFFFAOYSA-L 0.000 description 1
- 229910000363 nickel(II) sulfate Inorganic materials 0.000 description 1
- 208000007884 postpartum thyroiditis Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 239000005495 thyroid hormone Substances 0.000 description 1
- 229940036555 thyroid hormone Drugs 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/5436—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand physically entrapped within the solid phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
- C12Y111/01—Peroxidases (1.11.1)
- C12Y111/01008—Iodide peroxidase (1.11.1.8)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/583—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with non-fluorescent dye label
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/908—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/046—Thyroid disorders
Definitions
- Thyroid peroxidase is a membrane bound glycoprotein found in the apical membrane of thyroid follicular cells. TPO oxidizes iodide ions for addition onto thyroglobulin tyrosine residues for production of key thyroid hormones T 3 and T 4 . TPO is also an autoantigen in thyroid diseases, including, for example, Hashimoto's thyroiditis, Graves' disease, atrophic thyroiditis, primary mixedema, and postpartum thyroiditis in women. Elevated levels of anti-TPO autoantibody are a risk factor for thyroid diseases.
- the methods can comprise incubating the biological sample from the subject with a solid support, an unlabeled recombinant cynomolgus monkey thyroid peroxidase (rTPO), and a labeled cynomolgus monkey rTPO.
- rTPO unlabeled recombinant cynomolgus monkey thyroid peroxidase
- a complex comprising the labeled cynomolgus monkey rTPO, the unlabeled cynomolgus monkey rTPO, and the solid support is formed.
- the methods further comprise detecting the complex, the presence of which indicates the presence of the anti-thyroid peroxidase antibody in the biological sample.
- the methods can be an “antigen bridge” assay as described herein.
- Also provided are methods of detecting an anti-thyroid peroxidase antibody in a biological sample from a subject comprising incubating the biological sample from the subject with a solid support, a cynomolgus monkey rTPO, and an anti-human secondary antibody.
- a complex comprising the solid support, the cynomolgus monkey rTPO, and the anti-human secondary antibody is formed.
- the methods further comprise detecting the complex, the presence of which indicates the presence of the anti-thyroid peroxidase antibody in the biological sample.
- the methods can be an “rTPO capture” assay as described herein.
- the methods can be an “IgG class capture” assay as described herein.
- an anti-thyroid peroxidase antibody in a biological sample from a subject comprising incubating the biological sample from the subject with a solid support, an unlabeled anti-TPO antibody, a cynomolgus monkey rTPO, and a labeled anti-TPO antibody and detecting the anti-thyroid peroxidase antibody, the detecting comprising analyzing a decrease in the formation of a complex comprising the solid support, the unlabeled anti-TPO antibody, the cynomolgus monkey rTPO, and the labeled anti-TPO antibody.
- the presence of an anti-thyroid peroxidase antibody in the biological sample decreases formation of a complex comprising the solid support, the unlabeled anti-TPO antibody, the cynomolgus monkey rTPO, and the labeled anti-TPO antibody.
- the presence of complex is inversely proportional to the presence of the anti-thyroid peroxidase antibody in the biological sample.
- the methods can be a “competition” assay or an “inhibition” assay, as described herein.
- the methods can comprise incubating a biological sample from the subject with a solid support, an unlabeled recombinant cynomolgus monkey thyroid peroxidase (rTPO), and a labeled cynomolgus monkey rTPO.
- rTPO cynomolgus monkey thyroid peroxidase
- a complex comprising the labeled cynomolgus monkey rTPO, the unlabeled cynomolgus monkey rTPO, and the solid support is formed.
- the method further comprises diagnosing the subject with the thyroid disease if the complex is formed.
- Methods of diagnosing a thyroid disease in a subject comprising incubating a biological sample from the subject with a solid support, a cynomolgus monkey rTPO, and an anti-human secondary antibody are also provided. In the presence of an anti-thyroid peroxidase antibody in the biological sample, a complex comprising the solid support, the cynomolgus monkey rTPO, and the anti-human secondary antibody is formed. The method further comprises diagnosing the subject with the thyroid disease if the complex is formed.
- kits for diagnosing a thyroid disease in a subject comprising incubating a biological sample from a subject with a solid support, an unlabeled anti-TPO antibody, a cynomolgus monkey rTPO, and a labeled anti-TPO antibody, and diagnosing the subject with the thyroid disease if the formation of a complex comprising the solid support, the unlabeled anti-TPO antibody, the cynomolgus monkey rTPO, and the labeled anti-TPO antibody is decreased.
- an anti-thyroid peroxidase antibody in the biological sample decreases formation of a complex comprising the solid support, the unlabeled anti-TPO antibody, the cynomolgus monkey rTPO, and the labeled anti-TPO antibody.
- Recombinantly produced thyroid peroxidase comprising the amino acid sequence of SEQ ID NO: 1 is also disclosed, as are cDNA molecules encoding the recombinantly produced rTPO.
- kits comprise a solid support, an unlabeled cynomolgus monkey rTPO, and a labeled cynomolgus monkey rTPO.
- kits can comprise a solid support, a cynomolgus monkey rTPO, and an anti-human secondary antibody.
- kits comprise a solid support, a cynomolgus monkey rTPO and an anti-TPO antibody.
- FIG. 1 illustrates an exemplary reaction scheme for one embodiment of the disclosed methods, referred to herein as the antigen bridge immunoassay.
- FIG. 2 illustrates an exemplary reaction scheme for one embodiment of the disclosed methods, referred to herein as the IgG class capture immunoassay.
- FIG. 3 illustrates an exemplary reaction scheme for one embodiment of the disclosed methods, referred to herein as the rTPO capture immunoassay.
- FIG. 4 illustrates an exemplary reaction scheme for one embodiment of the disclosed methods, referred to herein as the competition/inhibition immunoassay.
- FIG. 5 illustrates the results from an exemplary rTPO lot-to-lot purity and immunoreactivity assessment.
- Panel A shows a gel stained with Gel Code Blue (ThermoFisher 25590);
- panel B shows a nitrocellulose membrane probed with a mouse anti-TPO monoclonal antibody followed by a goat anti-mouse IgG-HRP secondary. 4-chloro-1-naphthol (Sigma) was used to develop the blot.
- FIG. 6 illustrates the results from an exemplary rTPO isoelectric point assessment for 4 rTPO antigen lots.
- FIG. 7 A and FIG. 7 B illustrate the results from an exemplary assessment of immunoassay susceptibility to deglycosylated rTPO.
- FIG. 7 A shows a rTPO antigen bridge assay and
- FIG. 7 B shows a human IgG class capture assay built using various deglycosylated components.
- Hook Ratio refers to relative light units (RLU) of a 20,000 IU/mL sample divided by RLU of the highest standard at 625 IU/mL.
- BKGD refers to background RLU of an aTPO-negative serum patient pool, i.e., the lowest standard.
- S08/S01 refers to RLU of the highest standard at 625 IU/mL divided by the RLU of the lowest standard.
- SP means “solid phase” and “LR” means “Lite reagent”; “de” refers to “deglycosylation.”
- FIG. 8 illustrates the results from an exemplary characterization of rTPO complexed with autoantibodies from an anti-TPO antibody-positive disease patient sample, with relative light units (RLU) plotted on a chromatogram from size exclusion chromatography (SEC) fractions.
- RLU relative light units
- FIG. 9 is a chromatogram from an exemplary SEC analysis of pooled fractions from the fractions depicted in the rectangle in FIG. 8 .
- FIG. 10 A , FIG. 10 B , FIG. 10 C , and FIG. 10 D illustrate exemplary MALDI-TOF spectra of isolated fractions S1, S2, S3 and S4 from FIG. 9 .
- FIG. 11 illustrates the results from an analysis of immunoassay performance using native TPO and recombinant TPO (“rTPO”).
- FIG. 12 A , FIG. 12 B , FIG. 12 C , and FIG. 12 D illustrate the results from exemplary experiments performed using the disclosed immunoassays: FIG. 12 A ) antigen bridge, FIG. 12 B ) IgG class capture, FIG. 12 C ) rTPO capture, and FIG. 12 D ) competition/inhibition formats.
- Each assay was performed using the ADVIA CENTAUR® system.
- RLU output associated with standardization material value was assigned from WHO 66/387 Human Anti-thyroid Microsome Serum.
- any description as to a possible mechanism or mode of action or reason for improvement is meant to be illustrative only, and the disclosed methods and kits are not to be constrained by the correctness or incorrectness of any such suggested mechanism or mode of action or reason for improvement.
- the descriptions refer to methods of detecting an antibody and methods of diagnosing a thyroid disease. Where the disclosure describes or claims a feature or embodiment associated with a method of detecting an antibody, such a feature or embodiment is equally applicable to the methods of diagnosing a thyroid disease. Likewise, where the disclosure describes or claims a feature or embodiment associated with a method of diagnosing a thyroid disease, such a feature or embodiment is equally applicable to the methods of detecting an antibody.
- range includes the endpoints thereof and all the individual integers and fractions within the range, and also includes each of the narrower ranges therein formed by all the various possible combinations of those endpoints and internal integers and fractions to form subgroups of the larger group of values within the stated range to the same extent as if each of those narrower ranges was explicitly recited.
- range of numerical values is stated herein as being greater than a stated value, the range is nevertheless finite and is bounded on its upper end by a value that is operable within the context of the invention as described herein.
- an anti-thyroid peroxidase (anti-TPO) antibody in a biological sample from a subject and/or diagnosing a thyroid disease in a subject.
- the methods of detecting an anti-thyroid peroxidase antibody in a biological sample from a subject can comprise:
- the methods can comprise an “antigen bridge” immunoassay, an exemplary reaction scheme for which is illustrated in FIG. 1 .
- a biological sample known to have, or suspected of having, an anti-TPO antibody 10 is incubated with a labeled rTPO 20 and solid support having an unlabeled rTPO bound thereto 30 .
- the labeled rTPO 20 will not bind to or otherwise interact with the solid support.
- the labeled rTPO remains in the solution and isolation of the solid support would not result in isolation of the labeled rTPO.
- the anti-TPO antibody 10 When the anti-TPO antibody 10 is present in the biological sample, the anti-TPO antibody 10 simultaneously binds to the unlabeled rTPO bound to the solid support 30 and the labeled rTPO 20 , thereby linking the labeled rTPO 20 and the solid support 30 and resulting in the formation of a solid support/labeled rTPO complex 40 .
- the order in which the incubation takes place can be different from that exemplified in FIG. 1 .
- the biological sample known to have, or suspected of having, an anti-TPO antibody 10 can first be incubated with a solid support having an unlabeled rTPO bound thereto 30 followed by incubation with a labeled rTPO 20 .
- the biological sample known to have, or suspected of having, an anti-TPO antibody 10 can simultaneously be incubated with a solid support having an unlabeled rTPO bound thereto 30 and a labeled rTPO 20 .
- the biological sample known to have, or suspected of having, an anti-TPO antibody 10 can be incubated in a reaction mixture for a period of time sufficient to achieve a partial reaction without allowing the reaction to achieve equilibrium, such as for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, or less than about 10 minutes.
- the labeled rTPO 20 can be added and incubated with the biological sample for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, or less than about 5 minutes.
- the solid support having unlabeled rTPO bound thereto 30 can be added to the mixture of biological sample and labeled rTPO 20 and incubated for a period of time sufficient to achieve a partial reaction without allowing the reaction to achieve equilibrium, such as for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, or about less than 10 minutes.
- the incubating steps are performed in a total of about 10 minutes to about 20 minutes.
- the subsequent detecting can be performed in less than about 5 minutes.
- the amount of time needed for the assay may vary based upon several factors including the level of the anti-TPO antibody(ies) in the biological sample and the affinity of the anti-TPO antibody(ies) for the rTPO.
- incubating the biological sample with the reaction mixture can be performed for a period of time sufficient to enable the reaction to achieve equilibrium, such as on the order of 1 or more hours.
- the disclosed methods can be performed for any suitable amount of time.
- the unlabeled rTPO can be directly or indirectly linked to the solid support. Suitable techniques for directly linking the unlabeled rTPO to the solid support include, for example, covalent attachment, adsorption, noncovalent interaction, or combinations thereof. In some embodiments, the unlabeled rTPO can be directly linked to the solid support by N-hydroxysuccinimide (NHS) chemistry or by 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) NHS chemistry. Suitable techniques for indirectly linking the rTPO to the solid support include, for example, linking through a peptide, a protein, an antibody, a linker, or a combination thereof. In some embodiments, the unlabeled rTPO can be indirectly linked to the solid support through streptavidin and biotin. For example, the unlabeled rTPO can be biotinylated and the solid support can comprise streptavidin.
- Exemplary solid supports include, but are not limited to, a column matrix material, a culture plate, a tube, a dish, a flask, a microtiter plate, a bead/particle, heat-killed formalin- (or other chemically)-fixed prokaryotic or eukaryotic cells, microscope slides, ACLAR® Film, or any other optically transparent polymer, or a combination thereof.
- the solid support can be fully or partially composed of plastic, cellulose, cellulose derivatives, nitrocellulose, glass, fiberglass, latex, or a combination thereof.
- the solid support comprises a magnetic bead/particle.
- the magnetic bead/particle is a paramagnetic particle (PMP).
- the magnetic bead/particle is a latex magnetic particle (LMP).
- the label can be any suitable label known to those skilled in the art to be useful for creating a detectable signal.
- Suitable detectable labels include, but are not limited to, enzyme conjugates (e.g., horseradish peroxidase (HRP), alkaline phosphatase, glucose oxidase, and (3-galactosidase), fluorescent probes, radioactive isotopes, chemiluminescent compounds, bioluminescent compounds, or combination thereof.
- the label is an acridinium ester (“AE”) or an analog thereof.
- Suitable AE analogs include: dimethyl acridinium ester (DMAE), N-sulfopropyl dimethyl acridinium ester (NSP-DMAE), high quantum yield acridinium ester (HQYAE, acridinium, 9-[[4-[[[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]amino]carbonyl]-2,6-dimethylphenoxy]carbonyl]-2,7-bis(3,6,9,12,15,18-hexaoxanonadec-1-yloxy)-10-(3-sulfopropyl)-, inner salt), Zwitterionic acridinium ester (ZAE, Acridinium, 9-[[4-[[[3-[[3-[[5-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1,5-dioxopentyl]
- the labeled cynomolgus monkey rTPO comprises rTPO-NSP-DMAE.
- the rTPO-NSP-DMAE can be present at about 50 ng/ml to about 2 ⁇ g/ml. In some embodiments, the rTPO-NSP-DMAE can be present at about 220 ng/ml.
- the solid support having unlabeled rTPO bound thereto and/or the labeled rTPO can be present in a buffer comprising, for example, phosphate buffer, NaCl, EDTA, pluronic F-127, sodium azide, sorbitol, sulfhydryl modified bovine serum, or any combinations, variations, or equivalents thereof.
- the buffer comprises about 100 mM phosphate buffer, about 400 mM NaCl, about 1.9 g/L EDTA, about 0.2% (v/v) pluronic F-127, about 0.9 g/L sodium azide, about 10% sorbitol, and about 10 g/L sulfhydryl modified bovine serum albumin.
- Also provided are methods of detecting an anti-thyroid peroxidase antibody in a biological sample from a subject comprising:
- the anti-human secondary antibody can be directly or indirectly linked to the solid support and the cynomolgus monkey rTPO can comprise a label.
- the anti-human secondary antibody can be directly linked to the solid support by glutaraldehyde fixation.
- the methods can comprise an “IgG class capture” immunoassay, an exemplary reaction scheme for which is illustrated in FIG. 2 .
- a biological sample known to have, or suspected of having, an anti-TPO antibody 10 is incubated with a labeled rTPO 20 and a solid support having an unlabeled anti-human secondary antibody bound thereto 50 .
- the labeled rTPO 20 will not bind to or otherwise interact with the solid support.
- the labeled rTPO remains in the solution and isolation of the solid support would not result in isolation of the labeled rTPO.
- the anti-TPO antibody 10 When the anti-TPO antibody 10 is present in the biological sample, the anti-TPO antibody 10 simultaneously binds to the unlabeled anti-human secondary antibody bound to the solid support 50 and the labeled rTPO 20 , thereby linking the labeled rTPO 20 and the solid support 50 and resulting in the formation of a solid support/labeled rTPO complex 60 . It is to be understood that the order in which the incubation takes place can be different from that exemplified in FIG. 2 .
- the biological sample known to have, or suspected of having, an anti-TPO antibody 10 can first be incubated with a solid support having an unlabeled anti-human secondary antibody bound thereto 50 followed by incubation with a labeled rTPO 20 .
- the biological sample known to have, or suspected of having, an anti-TPO antibody 10 can simultaneously be incubated with a solid support having an unlabeled anti-human secondary antibody bound thereto 50 and a labeled rTPO 20 .
- the biological sample known to have, or suspected of having, an anti-TPO antibody 10 can be incubated in a reaction mixture for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, or less than about 10 minutes.
- the labeled rTPO 20 can be added and incubated with the biological sample for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, or less than about 5 minutes.
- the solid support having an unlabeled anti-human secondary antibody bound thereto 50 can be added to the mixture of biological sample and labeled rTPO 20 and incubated for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, or about less than 10 minutes.
- the incubating steps are performed in a total of about 10 minutes to about 20 minutes.
- the subsequent detecting can be performed in less than about 5 minutes. It is to be understood that the amount of time needed for the assay may vary based upon several factors including the level of the anti-TPO antibody(ies) in the biological sample and the affinity of the anti-TPO antibody(ies) for the rTPO. Thus, the disclosed methods can be performed for any suitable amount of time.
- the cynomolgus monkey rTPO can be directly or indirectly linked to the solid support and the anti-human secondary antibody can comprise a label.
- the rTPO can be directly linked to the solid support by N-hydroxysuccinimide (NHS) chemistry or by 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) NHS chemistry.
- NHS N-hydroxysuccinimide
- EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
- the methods can comprise an “rTPO capture” immunoassay, an exemplary reaction scheme for which is illustrated in FIG. 3 .
- a biological sample known to have, or suspected of having, an anti-TPO antibody 10 is incubated with a labeled anti-human secondary antibody 70 and a solid support having an unlabeled rTPO bound thereto 30 .
- the labeled anti-human secondary antibody 70 will not bind to or otherwise interact with the solid support.
- the labeled anti-human secondary antibody remains in the solution and isolation of the solid support would not result in isolation of the labeled anti-human secondary antibody.
- the anti-TPO antibody 10 When the anti-TPO antibody 10 is present in the biological sample, the anti-TPO antibody 10 simultaneously binds to the unlabeled rTPO bound to the solid support 30 and the labeled anti-human secondary antibody 70 , thereby linking the labeled anti-human secondary antibody 70 and the solid support 30 and resulting in the formation of a solid support/labeled anti-human secondary antibody complex 80 . It is to be understood that the order in which the incubation takes place can be different from that exemplified in FIG. 3 .
- the biological sample known to have, or suspected of having, an anti-TPO antibody 10 can first be incubated with a solid support having an unlabeled rTPO bound thereto 30 followed by incubation with a labeled anti-human secondary antibody 70 .
- the biological sample known to have, or suspected of having, an anti-TPO antibody 10 can simultaneously be incubated with a solid support having an unlabeled rTPO bound thereto 30 and a labeled anti-human secondary antibody 70 .
- the biological sample known to have, or suspected of having, an anti-TPO antibody 10 can be incubated in a reaction mixture for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, or less than about 10 minutes.
- the labeled anti-human secondary antibody 70 can be added and incubated with the biological sample for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, or less than about 5 minutes.
- the solid support having an unlabeled rTPO bound thereto 30 can be added to the mixture of biological sample and labeled anti-human secondary antibody 70 and incubated for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, or about less than 10 minutes.
- the incubating steps are performed in a total of about 10 minutes to about 20 minutes.
- the subsequent detecting can be performed in less than about 5 minutes. It is to be understood that the amount of time needed for the assay may vary based upon several factors including the level of the anti-TPO antibody(ies) in the biological sample and the affinity of the anti-TPO antibody(ies) for the rTPO. Thus, the disclosed methods can be performed for any suitable amount of time.
- the anti-human secondary antibody or the cynomolgus monkey rTPO can be directly or indirectly linked to the solid support by any suitable means known to those skilled in the art. Suitable techniques for direct linking include, for example, covalent attachment, adsorption, noncovalent interaction, or combinations thereof. In some embodiments, the anti-human secondary can be directly linked to the solid support by glutaraldehyde fixation. Suitable means for indirect linking include, for example, linking through a peptide, a protein, an antibody, a linker, or a combination thereof. In some embodiments, the anti-human secondary antibody or the cynomolgus monkey rTPO can be indirectly linked to the solid support through streptavidin and biotin. For example, the unlabeled anti-human secondary antibody or the unlabeled rTPO can be biotinylated and the solid support can comprise streptavidin.
- Exemplary solid supports include, but are not limited to, a column matrix material, a culture plate, a tube, a dish, a flask, a microtiter plate, a bead/particle, heat-killed formalin- (or other chemically)-fixed prokaryotic or eukaryotic cells, microscope slides, ACLAR® Film, or any other optically transparent polymer, or a combination thereof.
- the solid support can be fully or partially composed of plastic, cellulose, cellulose derivatives, nitrocellulose, glass, fiberglass, latex, or a combination thereof.
- the solid support comprises a magnetic bead/particle.
- the magnetic bead/particle is a paramagnetic particle (PMP).
- the magnetic bead/particle is a latex magnetic particle (LMP).
- the anti-human secondary antibody can be an IgA, IgD, IgG, IgE, or IgM isotype or a single domain format, such as a single-domain antibody from camelid.
- the anti-human secondary antibody is an anti-human IgG.
- the anti-human secondary antibody is a commercially available anti-human secondary antibody. Aptamers that are specific for the anti-TPO antibody can also be used.
- the label can be any suitable label known to those skilled in the art to be useful for creating a detectable signal.
- Suitable detectable labels include, but are not limited to, enzyme conjugates (e.g., horseradish peroxidase (HRP), alkaline phosphatase, glucose oxidase, and (3-galactosidase), fluorescent probes, radioactive isotopes, chemiluminescent compounds, bioluminescent compounds, or a combination thereof.
- the label can be an AE or an analog thereof.
- Suitable AE analogs include: dimethyl acridinium ester (DMAE), N-sulfopropyl dimethyl acridinium ester (NSP-DMAE), high quantum yield acridinium ester (HQYAE), Zwitterionic acridinium ester (ZAE), N-sulfopropyl-2-isopropoxy dimethyl acridinium ester (Iso-Di-ZAE), trisulfopropyl acridinium ester (TSP-AE), or N-sulfopropyl dimethyl acridinium ester with hexa(ethylene)glycol linker (HEG-GLU-AE).
- DMAE dimethyl acridinium ester
- NSP-DMAE N-sulfopropyl dimethyl acridinium ester
- HQYAE high quantum yield acridinium ester
- Zwitterionic acridinium ester ZAE
- the labeled cynomolgus monkey rTPO comprises rTPO-NSP-DMAE.
- the rTPO-NSP-DMAE can be present at about 50 ng/ml to about 2 ⁇ g/ml. In some embodiments, the rTPO-NSP-DMAE can be present at about 220 ng/ml.
- the solid support having unlabeled anti-human secondary antibody or unlabeled rTPO bound thereto and/or the labeled rTPO or labeled anti-human secondary antibody can be present in a buffer comprising, for example, phosphate buffer, NaCl, EDTA, pluronic F-127, sodium azide, sorbitol, sulfhydryl modified bovine serum, or any combinations, variations, or equivalents thereof.
- the buffer comprises about 100 mM phosphate buffer, about 400 mM NaCl, about 1.9 g/L EDTA, about 0.2% (v/v) pluronic F-127, about 0.9 g/L sodium azide, about 10% sorbitol, and about 10 g/L sulfhydryl modified bovine serum albumin.
- Also provided are methods of detecting an anti-thyroid peroxidase antibody in a biological sample from a subject comprising:
- Analyzing a decrease in the formation of the complex can be performed, for example, by comparing a read-out of a signal from the labeled anti-TPO antibody in a reaction mixture with the biological sample to a read-out of a signal from the labeled anti-TPO antibody in a reaction mixture without the biological sample. If the read-out of the signal from the reaction mixture with the biological sample is less than the read-out from the reaction mixture without the biological sample, formation of the complex is decreased.
- the amount of complex formed is inversely proportional to the presence of the anti-thyroid peroxidase antibody in the biological sample.
- the methods can comprise a “competition” immunoassay or an “inhibition” immunoassay, an exemplary reaction scheme for which is illustrated in FIG. 4 .
- a “competition” immunoassay refers to an immunoassay in which two or more binding molecules compete for binding to a target molecule.
- the binding molecules can be antibodies, for example, and the target molecule can be an antigen.
- the binding molecules can compete, for example, for binding to the same epitope(s) on the antigen.
- An “inhibition” immunoassay refers to an immunoassay in which one or more binding molecules inhibit binding of one or more other binding molecules to a target molecule.
- the binding molecules can be antibodies, for example, and the target molecule can be an antigen. Inhibition can be caused by steric hindrance or other known mechanisms of binding inhibition. Whether the claimed assays are classified as a “competition” or “inhibition” immunoassay will depend, for example, on the rTPO epitope recognized by the anti-thyroid peroxidase antibody in the biological sample and the labeled anti-TPO antibody.
- the claimed methods encompass both competition and inhibition immunoassays, and thus the terms “competition” and “inhibition” are not intended to limit the scope of the claimed methods.
- the labeled anti-TPO antibody and the rTPO can be in pre-formed immune complex prior to their addition to the reaction mixture.
- the unlabeled anti-TPO antibody and solid support can be in pre-formed complex prior to their addition to the reaction mixture.
- the labeled anti-TPO antibody, the rTPO, the unlabeled anti-TPO antibody, and the solid support are not in a pre-formed complex prior to their addition to the reaction mixture.
- the labeled anti-TPO antibody, the rTPO, the unlabeled anti-TPO antibody, and the solid support are all present in a pre-formed complex prior to their addition to the reaction mixture.
- Whether the various components are in one or more pre-formed complexes prior to their addition to the reaction mixture will depend, in part, on the dissociation constants (K D ) of the labeled and unlabeled antibodies and the rTPO.
- K D dissociation constants
- the disclosed methods are not limited by the type or extent of complex formation added to the reaction mixture. It is to be understood that the biological sample, the labeled anti-TPO antibody, the rTPO, the unlabeled anti-TPO antibody, and the solid support can be added to the reaction mixture in any order.
- FIG. 4 discloses one exemplary embodiment of the competition/inhibition immunoassays described herein, in which a labeled anti-TPO antibody 110 and an rTPO 120 are incubated with a solid support having an unlabeled anti-TPO antibody bound thereto 130 .
- the labeled anti-TPO antibody 110 will bind to the rTPO 120 and in turn bind to or interact with the solid support having unlabeled anti-TPO antibody bound thereto 130 , thereby forming a complex 140 comprising the labeled anti-TPO antibody 110 , the rTPO 120 , and the solid support.
- the labeled anti-TPO antibody 110 will be coupled to the solid support, isolation of which will result in isolation of the labeled anti-TPO antibody 110 .
- the anti-TPO antibody 10 will compete with or otherwise inhibit the labeled anti-TPO antibody 110 for binding to the rTPO 120 or will compete with or otherwise inhibit the unlabeled anti-TPO antibody bound to the solid support 130 for binding to the rTPO 120 , thereby preventing the complex from forming or displacing the labeled anti-TPO antibody from the complex 140 .
- the presence of complex 140 comprising the labeled anti-TPO antibody 110 , the rTPO 120 , and the solid support is decreased.
- the labeled anti-TPO antibody 110 , the unlabeled rTPO 120 , and the unlabeled anti-TPO antibody bound to the solid support 130 can be incubated in a reaction mixture for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, or less than about 10 minutes.
- the biological sample known to have, or suspected of having, an anti-TPO antibody 10 can be added and incubated in the reaction mixture for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, or less than about 10 minutes.
- the incubating steps are performed in a total of about 10 minutes to about 20 minutes.
- the subsequent detecting can be performed in less than about 5 minutes.
- the amount of time needed for the assay may vary based upon several factors including the level of the anti-TPO antibody(ies) in the biological sample and the affinity of the anti-TPO antibody(ies) for the rTPO.
- the disclosed methods can be performed for any suitable amount of time.
- the unlabeled anti-TPO antibody can be directly or indirectly coupled to the solid support. Suitable techniques for directly coupling the unlabeled anti-TPO antibody to the solid support include, for example, covalent attachment, adsorption, noncovalent interaction, or combinations thereof. Suitable means for indirectly coupling the unlabeled anti-TPO antibody to the solid support include, for example, linking through a peptide, a protein, an antibody, a linker, or a combination thereof. In some embodiments, the unlabeled anti-TPO antibody can be indirectly coupled to the solid support through streptavidin and biotin. For example, the unlabeled anti-TPO antibody can be biotinylated and the solid support can comprise streptavidin. The labeled and/or the unlabeled anti-TPO antibody can be any known commercially available anti-TPO antibody.
- Exemplary solid supports include, but are not limited to, a column matrix material, a culture plate, a tube, a dish, a flask, a microtiter plate, a bead/particle, heat-killed formalin- (or other chemically)-fixed prokaryotic or eukaryotic cells, microscope slides, ACLAR® Film, or any other optically transparent polymer, or a combination thereof.
- the solid support can be fully or partially composed of plastic, cellulose, cellulose derivatives, nitrocellulose, glass, fiberglass, latex, or a combination thereof.
- the solid support comprises a magnetic bead/particle.
- the magnetic bead/particle is a paramagnetic particle (PMP).
- the magnetic bead/particle is a latex magnetic particle (LMP).
- the label can be any suitable label known to those skilled in the art to be useful for creating a detectable signal.
- Suitable detectable labels include, but are not limited to, enzyme conjugates (e.g., horseradish peroxidase (HRP), alkaline phosphatase, glucose oxidase, and (3-galactosidase), fluorescent probes, radioactive isotopes, chemiluminescent compounds, bioluminescent compounds, or combination thereof.
- the label is an AE or an analog thereof.
- Suitable AE analogs include: dimethyl acridinium ester (DMAE), N-sulfopropyl dimethyl acridinium ester (NSP-DMAE), high quantum yield acridinium ester (HQYAE), Zwitterionic acridinium ester (ZAE), N-sulfopropyl-2-isopropoxy dimethyl acridinium ester (Iso-Di-ZAE), trisulfopropyl acridinium ester (TSP-AE), or N-sulfopropyl dimethyl acridinium ester with hexa(ethylene)glycol linker (HEG-GLU-AE).
- DMAE dimethyl acridinium ester
- NSP-DMAE N-sulfopropyl dimethyl acridinium ester
- HQYAE high quantum yield acridinium ester
- Zwitterionic acridinium ester ZAE
- the labeled anti-TPO antibody is anti-TPO IgG HEG-GLU-AE.
- the anti-rTPO IgG HEG-GLU-AE can be present at about 50 ng/ml to about 2 ⁇ g/ml. In some embodiments, the anti-rTPO IgG HEG-GLU-AE can be present at about 420 ng/ml.
- the solid support having unlabeled anti-TPO antibody bound thereto and/or the unlabeled rTPO and/or the labeled anti-TPO antibody can be present in a buffer comprising, for example, phosphate buffer, NaCl, EDTA, pluronic F-127, sodium azide, sorbitol, sulfhydryl modified bovine serum, or any combinations, variations, or equivalents thereof.
- a buffer comprising, for example, phosphate buffer, NaCl, EDTA, pluronic F-127, sodium azide, sorbitol, sulfhydryl modified bovine serum, or any combinations, variations, or equivalents thereof.
- the buffer comprises about 100 mM phosphate buffer, about 400 mM NaCl, about 1.9 g/L EDTA, about 0.2% (v/v) pluronic F-127, about 0.9 g/L sodium azide, about 10% sorbitol, and about 10 g/L sulfhydryl modified bovine serum albumin.
- methods of diagnosing a thyroid disease in a subject comprising incubating a biological sample from the subject with a solid support, an unlabeled recombinant cynomolgus monkey thyroid peroxidase (rTPO), and a labeled cynomolgus monkey rTPO.
- rTPO cynomolgus monkey thyroid peroxidase
- a complex comprising the labeled cynomolgus monkey rTPO, the unlabeled cynomolgus monkey rTPO, and the solid support is formed.
- the method further comprises diagnosing the subject with the thyroid disease if the complex is formed.
- Methods of diagnosing a thyroid disease in a subject comprising incubating a biological sample from the subject with a solid support, a cynomolgus monkey rTPO, and an anti-human secondary antibody are also provided. In the presence of an anti-thyroid peroxidase antibody in the biological sample, a complex comprising the solid support, the cynomolgus monkey rTPO, and the anti-human secondary antibody is formed. The method further comprises diagnosing the subject with the thyroid disease if the complex is formed.
- Also disclosed are methods of diagnosing a thyroid disease in a subject comprising incubating a biological sample from a subject with a solid support, an unlabeled anti-TPO antibody, a cynomolgus monkey TPO, and a labeled anti-TPO antibody, and diagnosing the thyroid disease if the formation of a complex comprising the solid support, the unlabeled anti-TPO antibody, the cynomolgus monkey rTPO, and the labeled anti-TPO antibody is decreased.
- an anti-thyroid peroxidase antibody in the biological sample decreases formation of a complex comprising the solid support, the unlabeled anti-TPO antibody, the cynomolgus monkey rTPO, and the labeled anti-TPO antibody.
- the labeled and/or the unlabeled anti-TPO antibody can be any known or commercially available anti-TPO antibody.
- the methods of diagnosing can further comprise a step of detecting the complex.
- detecting the complex may comprise taking a read-out of a signal from the label, wherein the intensity of the signal from the label indicates the amount of label present in the assay.
- the thyroid disease can be an autoimmune disorder.
- the autoimmune disorder is Hashimoto's thyroiditis or Graves' disease.
- the unlabeled rTPO, the unlabeled anti-human secondary antibody, or the unlabeled anti-TPO antibody can be directly or indirectly linked/coupled to the solid support.
- Suitable techniques for direct linking/coupling include, for example, covalent attachment, adsorption, noncovalent interaction, or combinations thereof.
- the direct linking/coupling can be achieved by glutaraldehyde fixation, N-hydroxysuccinimide (NHS) chemistry, or 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) NHS chemistry.
- Suitable means for indirect linking/coupling include, for example, linking/coupling through a peptide, a protein, an antibody, a linker, or a combination thereof.
- the indirect linking/coupling to the solid support is via streptavidin and biotin.
- the unlabeled rTPO, the unlabeled anti-human secondary antibody, or the unlabeled anti-TPO antibody can be biotinylated and the solid support can comprise streptavidin.
- Exemplary solid supports include, but are not limited to, a column matrix material, a culture plate, a tube, a dish, a flask, a microtiter plate, a bead/particle, heat-killed formalin- (or other chemically)-fixed prokaryotic or eukaryotic cells, microscope slides, ACLAR® Film, or any other optically transparent polymer, or a combination thereof.
- the solid support can be fully or partially composed of plastic, cellulose, cellulose derivatives, nitrocellulose, glass, fiberglass, latex, or a combination thereof.
- the solid support comprises a magnetic bead/particle.
- the magnetic bead/particle is a paramagnetic particle (PMP).
- the magnetic bead/particle is a latex magnetic particle (LMP).
- the label can be any suitable label known to those skilled in the art to be useful for creating a detectable signal.
- Suitable detectable labels include, but are not limited to, enzyme conjugates (e.g., horseradish peroxidase (HRP), alkaline phosphatase, glucose oxidase, and ⁇ -galactosidase), fluorescent probes, radioactive isotopes, chemiluminescent compounds, bioluminescent compounds, or combination thereof.
- the label is an AE or an analog thereof.
- Suitable AE analogs include: dimethyl acridinium ester (DMAE), N-sulfopropyl dimethyl acridinium ester (NSP-DMAE), high quantum yield acridinium ester (HQYAE), Zwitterionic acridinium ester (ZAE), N-sulfopropyl-2-isopropoxy dimethyl acridinium ester (Iso-Di-ZAE), trisulfopropyl acridinium ester (TSP-AE), or N-sulfopropyl dimethyl acridinium ester with hexa(ethylene)glycol linker (HEG-GLU-AE).
- DMAE dimethyl acridinium ester
- NSP-DMAE N-sulfopropyl dimethyl acridinium ester
- HQYAE high quantum yield acridinium ester
- Zwitterionic acridinium ester ZAE
- the labeled cynomolgus monkey rTPO comprises rTPO-NSP-DMAE.
- the rTPO-NSP-DMAE can be present at about 50 ng/ml to about 2 ⁇ g/ml. In some embodiments, the rTPO-NSP-DMAE can be present at about 220 ng/ml.
- the labeled anti-TPO antibody is anti-rTPO IgG HEG-GLU-AE.
- the anti-rTPO IgG HEG-GLU-AE can be present at about 50 ng/ml to about 2 ⁇ g/ml. In some embodiments, the anti-rTPO IgG HEG-GLU-AE can be present at about 420 ng/ml.
- Suitable times for performing the methods of diagnosing an autoimmune disease include those provided above for the various methods of detecting an antibody.
- the methods can further comprise determining a level of the anti-thyroid peroxidase antibody in the biological sample of the subject.
- the level of the anti-thyroid peroxidase antibody in the biological sample of the subject is directly proportional to the level of the complex detected.
- the level of anti-TPO antibody can be determined by determining the level of solid support coupled to or in complex with the labeled component (i.e. the labeled rTPO or antibody). Determining the level of solid support coupled to or in complex with the labeled component can be performed, for example, by measuring the signal from the complex.
- the solid support coupled to or in complex with the labeled component is detected by measuring the signal or absence thereof from the labeled component linked to the solid support.
- the disclosed methods can be performed manually or can be automated.
- the disclosed methods can be performed using an ADVIA CENTAUR® Immunoassay System or an ATELLICATM system.
- the anti-TPO antibody is a patient anti-TPO antibody. In some embodiments, the anti-TPO antibody is an autoantibody.
- Suitable biological samples for detecting the anti-TPO antibody include any biological sample from a subject that contains, or is suspected of containing, the anti-TPO antibody including, but not limited to, serum, plasma, whole blood, saliva, urine, semen, perspiration, tears, and body tissues.
- the immunoassays disclosed herein employ a recombinant thyroid peroxidase (rTPO).
- the rTPO is from cynomolgus monkey.
- the rTPO comprises the amino acid sequence set forth in SEQ ID NO: 1 (Table 1).
- the rTPO further comprises an epitope tag.
- the epitope tag can be at the N-terminus or at the C-terminus of the rTPO.
- the epitope tag can be any suitable tag known to persons skilled in the art including, but not limited to, a 6-histidine tag, a hemagglutinin tag, a glutathione-S-transferase, a maltose binding protein, or a chitin binding protein.
- the rTPO comprises a C-terminal 6-histidine tag.
- kits can comprise a solid support, an unlabeled cynomolgus monkey rTPO, and a labeled cynomolgus monkey rTPO.
- kits can comprise a solid support, a cynomolgus monkey rTPO, and an anti-human secondary antibody.
- the cynomolgus monkey rTPO comprises a label or the anti-human secondary antibody comprises a label.
- kits can comprise a solid support, a cynomolgus monkey TPO and an anti-TPO antibody.
- a portion of the anti-TPO antibodies are unlabeled and a portion of the anti-TPO antibodies are labeled.
- Suitable solid supports and labels for any of the kits disclosed herein include those solid supports and labels disclosed for the methods above.
- Monkey thyroid tissue was obtained from cynomolgus monkey and mRNA was isolated and purified using Trizol/Chloroform extraction (Invitrogen, catalogue #15596026). A cDNA library was prepared using Invitrogen Thermo-Script RT-PCR kit.
- a soluble form of TPO was amplified from the cDNA library and the PCR product was purified using a Qiagen PCR purification kit (QIAquick PCR Purification Kit, catalogue #28104).
- the purified PCR product was digested with XbaI (New England Biolabs cat #R0145S) and NotI (New England Biolabs cat #R0189S) restriction endonucleases and gel-extracted.
- the gel-extracted TPO was ligated into a baculovirus expression vector.
- the vector was transformed in competent cells and plated on ampicillin-selected plates.
- cDNA encodes a cynomolgus monkey rTPO having the amino acid sequence of SEQ ID NO. 1 (Table 1).
- Baculoviral DNA was combined with a transfer plasmid comprising the rTPO sequence and incubated with Grace's media and transfection reagent (Invitrogen, Bac-N-Blue Transfection Kit, catalogue #K855-01). After transfection of Spodoptra frugiperda (Sf) cells, cell culture supernatants were subsequently screened for recombinant viruses and selected recombinants were purified, amplified and sequenced to confirm the identity of rTPO.
- Grace's media and transfection reagent Invitrogen, Bac-N-Blue Transfection Kit, catalogue #K855-01
- Spodoptra frugiperda (Sf) cells cell culture supernatants were subsequently screened for recombinant viruses and selected recombinants were purified, amplified and sequenced to confirm the identity of rTPO.
- Purified recombinant baculovirus containing the rTPO was used to infect cultures of Trichoplusia ni PRO (Tni PRO) in ESF921 cell culture medium. Transduced rTPO was secreted into the cell culture supernatant.
- rTPO was isolated from the supernatant using Chelating Sepharose Fast Flow immobilized metal (Nickel) affinity chromatography followed by size exclusion chromatography. Briefly, the chelating sepharose gel (GE Healthcare Catalog No. 17-0575-01) was charged with 100 mM NiSO 4 . rTPO in the culture supernatant was allowed to bind to the gel for 1.5 hours. Non-specific proteins were removed by washing the gel with 0.5 M Sodium Chloride, 0.05 M Tris pH 8.0, 10 mM Imidazole. rTPO was then eluted with 0.5 M Sodium Chloride, 0.05 M Tris pH 8.0, 0.1 M Imidazole. The elution fraction was then subjected to S-200 size exclusion chromatography on AKTA Prime Plus liquid chromatography system, and fractions containing rTPO were pooled.
- Chelating Sepharose Fast Flow immobilized metal (Nickel) affinity chromatography was charged with 100 m
- the final pool containing pure rTPO was analyzed by SDS/PAGE, followed by Coomassie Blue staining ( FIG. 5 , panel A) or western blotting ( FIG. 5 , panel B).
- rTPO was electrophoresed on 4-20% Tris-Glycine gels under non-reducing conditions for about 30-40 minutes at 200 V.
- the proteins were transferred onto nitrocellulose membrane and were probed with a mouse anti-TPO monoclonal antibody for one hour, followed by an horse radish peroxidase (HRP) conjugated, goat anti-mouse IgG polyclonal antibody (Millipore, lot 17011271) for 30 minutes; blots were developed with substrate (Surmodics BCIB) for about 5 minutes.
- the extent of rTPO glycosylation was determined by ion exchange chromatography, matrix-assisted LASER desorption time-of-flight (“MALDI-TOF”) mass spectrometry, and isoelectric focusing.
- MALDI-TOF matrix-assisted LASER desorption time-of-flight
- isoelectric focusing two protein species were identified, which appeared to be the result of glycosylation. As shown in FIG. 6 , the major band had an average pI 6.2 and the minor band had an average pI 5.2.
- Digested rTPO was subsequently analyzed by MALDI-TOF analysis using the Shimadzu AXIMA Confidence MALDI-TOF Mass Spectrometer. Enzyme digestion conditions for each reaction are summarized in Table 2 below. After 37° C. overnight incubation, samples were collected, cooled to room temperature, and de-salted. A 10 kDa MWCO centrifugal filter (Millipore; ref #UFC501024) was washed with 250 ⁇ l diH 2 O and spun for 10 minutes at 14,000 rpm. Samples were de-salted by adding digested sample to washed centrifugal filter, spinning at 14,000 rpm for 10 minutes, and decanting the flow-through. After each spin, 250 ⁇ l diH 2 O was aliquoted into the centrifugal filter and spun again at 14,000 rpm for 10 minutes for a total of three washes.
- Sample Ratio (Sample-to-Matrix) De-glycosylation Mix 1:2 EndoH 1:1 Neuraminidase 1:2 O-glycosidase 1:2 PNGaseF 1:1 Undigested rTPO 1:2
- MALDI-TOF analyses of three lots of rTPO showed slight lot-to-lot differences in glycosylation (data not shown).
- Digestion with De-glycosylation Mix showed the most pronounced molecular weight shift; this enzyme was chosen for de-glycosylation and subsequent conjugation for functional testing on ADVIA CENTAUR® XP immunoassay (Siemens Healthcare).
- N-hydroxysuccinimide (NHS) chemistry was used to prepare native human TPO (Fitzgerald 80-1382) labeled with NSP-DMAE and recombinant cynomolgus monkey TPO labeled with NSP-DMAE.
- Human TPO-NSP-DMAE or rTPO-NSP-DMAE was added at 4.75 minutes, followed by reagent containing latex magnetic particles at 7.5 minutes. Magnetic separation was initiated at 13.0 minutes to isolate the latex magnetic particles.
- sample was added at time zero and first-pass human TPO-NSP-DMAE or rTPO-NSP-DMAE was added at 6 minutes, followed by first-pass magnetic separation at 24.0 minutes.
- Second-pass human TPO-NSP-DMAE or rTPO-NSP-DMAE was added at 35.0 minutes, and second-pass magnetic separation was initiated at 52.75 minutes.
- the magnetic particles were prepared by washing with phosphate buffered saline three times and resuspending in 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin.
- the particles were magnetically separated and resuspended in either water or tween-20 PBS according to the Centaur platform cycle parameters. Siemens aTPO Master Curve Material (Siemens 10630890) were run as samples. As shown in FIG. 11 , recombinant TPO gave a higher signal-to-noise ratio compared to native TPO using both 7.5 minute one-pass and 20/20 minute two-pass formats on the ADVIA CENTAUR® XP.
- the rTPO antigen bridge immunoassay used biotinylated rTPO directly coupled to streptavidin-coated latex magnetic particles in 0.6 mg/mL in 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin, and rTPO coupled to TSP-AE (30 ng/mL rTPO-TSP-AE in 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin).
- the rTPO antigen bridge format was run as a 7.5 minute one-pass (TTFR: 18 minutes) assay and required a 1:6 onboard, sample predilution.
- TTFR 7.5 minute one-pass
- 20 ⁇ L of diluted sample was added to a second cuvette and incubated for 4.75 minutes.
- 100 ⁇ L of rTPO-TSP-AE was added and incubated for 2.75 minutes.
- 100 ⁇ L of rTPO/latex magnetic particles was then added and incubated for 2.75 minutes. Magnetic separation was initiated at 13.0 minutes.
- the magnetic particles were washed with phosphate buffered saline three times, and finally resuspended to their original concentration with 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin.
- the particles were magnetically separated and resuspended in either water or tween-20 PBS according to the Centaur platform cycle parameters.
- An exemplary schematic of the Antigen Bridge assay format is shown in FIG. 1 .
- the performance of an optimized rTPO antigen bridge immunoassay (optimized to minimize background, increase signal-to-noise and limit any prozone effect) is provided in FIG. 12 A .
- the human IgG class capture immunoassay used anti-human IgG monoclonal antibody directly coupled to paramagnetic particles by glutaraldehyde fixation and rTPO coupled to NSP-DMAE (0.34 mg/mL anti-human IgG/paramagnetic particles and 220 ng/mL rTPO-NSP-DMAE, both in 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin).
- the human IgG class capture format was run as a 7.5 minute one-pass (TTFR: 18 minutes) assay and required a 1:10 onboard, sample predilution.
- TTFR 7.5 minute one-pass
- 20 ⁇ L of diluted sample was added to a second cuvette and incubated for 4.75 minutes.
- 100 ⁇ L of rTPO-NSP-DMAE was added and incubated for 2.75 minutes.
- 200 ⁇ L of anti-human IgG/paramagnetic particles was added and incubated for 2.75 minutes. Magnetic particles were separated and washed as described above.
- An exemplary schematic of the IgG Class Capture assay format is depicted in FIG. 2 .
- the performance of an optimized human IgG class capture immunoassay (optimized to minimize background, increase signal-to-noise and limit any prozone effect) is provided in FIG. 12 B .
- the rTPO capture immunoassay used rTPO directly coupled to latex magnetic particles using 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) NHS chemistry and a monoclonal anti-human IgG antibody coupled to NSP-DMAE (0.4 mg/mL rTPO/latex magnetic particles and 1.6 ⁇ g/mL anti-human IgG antibody-NSP-DMAE, both in 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin).
- EDC 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide
- the rTPO capture format was run as a 7.5 minute one-pass (TTFR: 18 minutes) assay and required a 1:10 onboard, sample predilution.
- TTFR 15 minute one-pass
- 20 ⁇ L of diluted sample was added to a second cuvette.
- 100 ⁇ L of anti-human IgG antibody-NSP-DMAE was added and incubated for 2.75 minutes.
- 100 ⁇ L of rTPO/latex magnetic particles was added and incubated for 2.75 minutes. Magnetic particles were separated and washed as described above.
- An exemplary schematic of the rTPO Capture assay format is depicted in FIG. 3 .
- the performance of an optimized rTPO capture immunoassay (optimized to minimize background, increase signal-to-noise and limit any prozone effect) is provided in FIG. 12 C .
- the competition/inhibition immunoassay used a biotinylated monoclonal mouse anti-rTPO IgG antibody coupled to streptavidin-coated latex magnetic particles and monoclonal mouse anti-rTPO IgG antibody coupled to HEG-GLU-AE in immune complex with unlabeled rTPO (respectively, 0.3 mg/mL mouse-anti-rTPO/latex magnetic particles and 420 ng/mL rTPO:anti-rTPO IgG HEG-GLU-AE, both in 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin).
- the competition/inhibition format was run as a 7.5 minute one-pass (TTFR: 18 minutes) assay.
- TTFR 15 minute one-pass
- 20 ⁇ L of undiluted sample was added to a cuvette and incubated for 4.75 minutes.
- 75 ⁇ L of rTPO:anti-rTPO IgG HEG-GLU-AE and 150 ⁇ L of mouse-anti-rTPO/latex magnetic particles were added and incubated for 2.75 minutes each. Magnetic particles were separated and washed as described above.
- An exemplary schematic of the competition/inhibition assay format is shown in FIG. 4 .
- the performance of an optimized competition/inhibition immunoassay (optimized to minimize background, increase signal-to-noise and limit any prozone effect) is provided in FIG. 12 D .
- immunoassays were run using the Antigen Bridge and IgG Class Capture (with labeled rTPO detection) formats. Table 4 outlines immunoassay preparation for each format. Immunoassays were run in triplicate on an ADVIA CENTAUR® XP. Samples were prepared using anti-TPO antibody-Positive Plasma spiked into PBS Buffer targeting the following doses: 0, 12.5, 25, 50, 100, 200, 300, 400, 625, 20,000 IU/mL.
- IgG Class Capture assay format 30 ⁇ L of sample was added to a cuvette, followed by 180 ⁇ L diluent (100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, 10 g/L sulfhydryl modified bovine serum albumin), and the diluted sample was incubated for 4.75 minutes. 30 ⁇ L of the diluted sample was added to 100 ⁇ L diluent containing labeled rTPO, and incubated for 2.75 minutes.
- diluent 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, 10 g/L sulfhydryl modified bovine serum albumin
- FIG. 7 A and FIG. 7 B A functional assessment of rTPO, based on glycosylation, revealed that differences in rTPO glycosylation result in subtle variation in immunoreactivity (as measured by ADVIA CENTAUR® XP) against an anti-TPO antibody-positive patient pool ( FIG. 7 A and FIG. 7 B ).
- the immunoassays demonstrated low background and a wide dynamic range for effective aTPO detection and quantification.
- FPLC size exclusion chromatography was employed to verify the in vitro formation of a recombinant TPO-anti-TPO autoantibody complex and to confirm that the anti-TPO autoantibody, rather than some other component within the patient sample, was interacting with the recombinant TPO.
- rTPOAE baseline chromatogram rTPO labeled with N-sulfopropyl dimethyl acridinium ester (NSP-DMAE) (5 molar excess) was diluted to get ⁇ 5 million RLU (1:600 dilution) using fractionation buffer; 50 mM Sodium Phosphate, 150 mM sodium Chloride, 0.5% Tween 20, and 0.1% Sodium Azide at pH 7.4. This sample was analyzed by AKTA pure system with Superdex 200 HiLoad 16/600 column using the fractionation buffer, 500 ⁇ L injection and 1 ml/minute elution; 180 fractions (1 ml each) were collected and run on Berthold AutoLumat system to generate a baseline RLU chromatogram.
- NSP-DMAE N-sulfopropyl dimethyl acridinium ester
- rTPOAE refers to rTPO labeled with an acridinium ester analog or variant, e.g., NSP-DMAE in the present example.
- In vitro immune complex chromatogram A high anti-TPO antibody patient sample pool (concentration ⁇ 60,000 U/mL) was diluted to ⁇ 1,500 U/mL with the fractionation buffer. One part of the diluted sample was mixed with 19 parts of the diluted (1:600) rTPO labeled with dimethyl acridinium ester (NSP-DMAE). The sample mixture was analyzed using the same column and conditions as above.
- the RLU chromatogram of the mixture overlaid with the baseline chromatogram in FIG. 8 (“rTPOAE_spiker”) shows a higher molecular weight immune complex peak (fractions 45-55) along with the unbound labeled rTPO peak (Fractions 66-76).
- MALDI-TOF was used to evaluate the components of the immune complex.
- Sample preparation A high anti-TPO antibody patient pool (concentration ⁇ 20,000 IU/mL) was diluted to ⁇ 2,700 IU/mL with the fractionation buffer. The diluted sample was mixed with rTPO in a 1:1 ratio. The sample mixture was analyzed by AKTA Pure system with Superdex 200 HiLoad 16/60 column and 180 (1 ml each) fractions were collected.
- the A280 Chromatogram ( FIG. 9 ) shows three distinct peaks; a higher molecular weight Peak A (retention volume 52.05 mL), Peak B (retention volume 66.87 mL) and Peak C (retention volume 75.43 mL). Each of the peak area fractions were pooled separately; the higher molecular weight peak area was pooled into two samples.
- the pooled samples: S1 (fractions 46-49), S2 (fractions 51-54), S3 (fractions 65-68) and S4 (fractions 74-77) were concentrated using Amicon Ultra-4 Centrifugal Filters (Ultracel 30K 30,000 NMWL ref UFC803024).
- MALDI-TOF procedure Deionized water (“diH2O”) was added (500 ⁇ L) to a pre-washed Pall NanoSep filter followed by various volumes of the above S1, S2, S3, and S4 samples. The samples were then centrifuged at 12,000 ⁇ g for seven minutes and washed one more time with water and reconstituted directly with a sinapinic acid (Sigma-Aldrich 49508) trifluoroacetic acid (Alfa-Aesar 44630) matrix solution to achieve 2 mg/mL protein concentration. Two microliters of each sample was directly plotted to the MALDI-TOF plate and allowed to dry. A second spotting was performed to improve sensitivity.
- the MALDI-TOF was calibrated using a MALDI-grade BSA standard on a Shimadzu Axima Confidence MALDI-TOF with laser power was set at 65.
- the MALDI-TOF result ( FIG. 10 ) showed that samples S1 and S2 primarily consisted of a ⁇ 90 KDa protein species (rTPO) and ⁇ 150 KDa proteins representing human TPO autoantibodies.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Disclosed herein are immunoassays for detecting an anti-thyroid peroxidase antibody in a biological sample from a subject and/or diagnosing a thyroid disease in a subject. The disclosed immunoassays employ a recombinant cynomolgus monkey thyroid peroxidase (rTPO) and assess the level of anti-thyroid peroxidase antibody-induced formation or disruption of complexes comprising a solid support and the rTPO.
Description
- This application is a continuation of U.S. application Ser. No. 17/658,119 filed on Apr. 6, 2022, which is a divisional application claiming priority to U.S. application Ser. No. 17/250,182 filed on Dec. 10, 2020 which is a United States National Stage application of International Application No. PCT/US2019/040161 filed on Jul. 1, 2019 which claims priority of U.S. Provisional Application No. 62/693,434 filed Jul. 2, 2018, all of which are incorporated by reference herein in their entirety.
- Disclosed herein are methods of detecting an anti-thyroid peroxidase antibody in a biological sample from a subject and methods of diagnosing a thyroid disease in the subject.
- The instant application contains a Sequence Listing which has been submitted electronically in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 12, 2021, is named 2018P03766WO_ST25.tx and is 7,533 bytes in size.
- Thyroid peroxidase (TPO) is a membrane bound glycoprotein found in the apical membrane of thyroid follicular cells. TPO oxidizes iodide ions for addition onto thyroglobulin tyrosine residues for production of key thyroid hormones T3 and T4. TPO is also an autoantigen in thyroid diseases, including, for example, Hashimoto's thyroiditis, Graves' disease, atrophic thyroiditis, primary mixedema, and postpartum thyroiditis in women. Elevated levels of anti-TPO autoantibody are a risk factor for thyroid diseases.
- Current immunoassays for detecting patient anti-TPO autoantibody utilize human-derived TPO, which is obtained from human cadaver thyroid tissue. Human-derived TPO, however, is costly, difficult to purify, and low-yield, and can vary significantly from lot to lot. The current immunoassays further require multiple non-human secondary antibodies.
- Disclosed herein are methods of detecting an anti-thyroid peroxidase antibody in a biological sample from a subject. The methods can comprise incubating the biological sample from the subject with a solid support, an unlabeled recombinant cynomolgus monkey thyroid peroxidase (rTPO), and a labeled cynomolgus monkey rTPO. In the presence of the anti-thyroid peroxidase antibody, a complex comprising the labeled cynomolgus monkey rTPO, the unlabeled cynomolgus monkey rTPO, and the solid support is formed. The methods further comprise detecting the complex, the presence of which indicates the presence of the anti-thyroid peroxidase antibody in the biological sample. In some embodiments, the methods can be an “antigen bridge” assay as described herein.
- Also provided are methods of detecting an anti-thyroid peroxidase antibody in a biological sample from a subject, the methods comprising incubating the biological sample from the subject with a solid support, a cynomolgus monkey rTPO, and an anti-human secondary antibody. In the presence of the anti-thyroid peroxidase antibody, a complex comprising the solid support, the cynomolgus monkey rTPO, and the anti-human secondary antibody is formed. The methods further comprise detecting the complex, the presence of which indicates the presence of the anti-thyroid peroxidase antibody in the biological sample. In some embodiments, the methods can be an “rTPO capture” assay as described herein. In some embodiments, the methods can be an “IgG class capture” assay as described herein.
- Further provided are methods of detecting an anti-thyroid peroxidase antibody in a biological sample from a subject, the methods comprising incubating the biological sample from the subject with a solid support, an unlabeled anti-TPO antibody, a cynomolgus monkey rTPO, and a labeled anti-TPO antibody and detecting the anti-thyroid peroxidase antibody, the detecting comprising analyzing a decrease in the formation of a complex comprising the solid support, the unlabeled anti-TPO antibody, the cynomolgus monkey rTPO, and the labeled anti-TPO antibody. The presence of an anti-thyroid peroxidase antibody in the biological sample decreases formation of a complex comprising the solid support, the unlabeled anti-TPO antibody, the cynomolgus monkey rTPO, and the labeled anti-TPO antibody. The presence of complex is inversely proportional to the presence of the anti-thyroid peroxidase antibody in the biological sample. In some embodiments, the methods can be a “competition” assay or an “inhibition” assay, as described herein.
- Further disclosed herein are methods of diagnosing a thyroid disease in a subject. The methods can comprise incubating a biological sample from the subject with a solid support, an unlabeled recombinant cynomolgus monkey thyroid peroxidase (rTPO), and a labeled cynomolgus monkey rTPO. In the presence of an anti-thyroid peroxidase antibody in the biological sample, a complex comprising the labeled cynomolgus monkey rTPO, the unlabeled cynomolgus monkey rTPO, and the solid support is formed. The method further comprises diagnosing the subject with the thyroid disease if the complex is formed.
- Methods of diagnosing a thyroid disease in a subject comprising incubating a biological sample from the subject with a solid support, a cynomolgus monkey rTPO, and an anti-human secondary antibody are also provided. In the presence of an anti-thyroid peroxidase antibody in the biological sample, a complex comprising the solid support, the cynomolgus monkey rTPO, and the anti-human secondary antibody is formed. The method further comprises diagnosing the subject with the thyroid disease if the complex is formed.
- Further provided are methods of diagnosing a thyroid disease in a subject comprising incubating a biological sample from a subject with a solid support, an unlabeled anti-TPO antibody, a cynomolgus monkey rTPO, and a labeled anti-TPO antibody, and diagnosing the subject with the thyroid disease if the formation of a complex comprising the solid support, the unlabeled anti-TPO antibody, the cynomolgus monkey rTPO, and the labeled anti-TPO antibody is decreased. The presence of an anti-thyroid peroxidase antibody in the biological sample decreases formation of a complex comprising the solid support, the unlabeled anti-TPO antibody, the cynomolgus monkey rTPO, and the labeled anti-TPO antibody.
- Recombinantly produced thyroid peroxidase (rTPO) comprising the amino acid sequence of SEQ ID NO: 1 is also disclosed, as are cDNA molecules encoding the recombinantly produced rTPO.
- Further disclosed herein are kits. In some embodiments, the kits comprise a solid support, an unlabeled cynomolgus monkey rTPO, and a labeled cynomolgus monkey rTPO.
- Alternatively, the kits can comprise a solid support, a cynomolgus monkey rTPO, and an anti-human secondary antibody.
- In some embodiments, the kits comprise a solid support, a cynomolgus monkey rTPO and an anti-TPO antibody.
- The summary, as well as the following detailed description, is further understood when read in conjunction with the appended drawings. For the purpose of illustrating the disclosed methods and kits, there are shown in the drawings exemplary embodiments of the methods and kits; however, the methods and kits are not limited to the specific embodiments disclosed. In the drawings:
-
FIG. 1 illustrates an exemplary reaction scheme for one embodiment of the disclosed methods, referred to herein as the antigen bridge immunoassay. -
FIG. 2 illustrates an exemplary reaction scheme for one embodiment of the disclosed methods, referred to herein as the IgG class capture immunoassay. -
FIG. 3 illustrates an exemplary reaction scheme for one embodiment of the disclosed methods, referred to herein as the rTPO capture immunoassay. -
FIG. 4 illustrates an exemplary reaction scheme for one embodiment of the disclosed methods, referred to herein as the competition/inhibition immunoassay. -
FIG. 5 illustrates the results from an exemplary rTPO lot-to-lot purity and immunoreactivity assessment. Panel A shows a gel stained with Gel Code Blue (ThermoFisher 25590); panel B shows a nitrocellulose membrane probed with a mouse anti-TPO monoclonal antibody followed by a goat anti-mouse IgG-HRP secondary. 4-chloro-1-naphthol (Sigma) was used to develop the blot. -
FIG. 6 illustrates the results from an exemplary rTPO isoelectric point assessment for 4 rTPO antigen lots. -
FIG. 7A andFIG. 7B illustrate the results from an exemplary assessment of immunoassay susceptibility to deglycosylated rTPO.FIG. 7A shows a rTPO antigen bridge assay andFIG. 7B shows a human IgG class capture assay built using various deglycosylated components. “Hook Ratio” refers to relative light units (RLU) of a 20,000 IU/mL sample divided by RLU of the highest standard at 625 IU/mL. “BKGD” refers to background RLU of an aTPO-negative serum patient pool, i.e., the lowest standard. “S08/S01” refers to RLU of the highest standard at 625 IU/mL divided by the RLU of the lowest standard. “SP” means “solid phase” and “LR” means “Lite reagent”; “de” refers to “deglycosylation.” -
FIG. 8 illustrates the results from an exemplary characterization of rTPO complexed with autoantibodies from an anti-TPO antibody-positive disease patient sample, with relative light units (RLU) plotted on a chromatogram from size exclusion chromatography (SEC) fractions. -
FIG. 9 is a chromatogram from an exemplary SEC analysis of pooled fractions from the fractions depicted in the rectangle inFIG. 8 . -
FIG. 10A ,FIG. 10B ,FIG. 10C , andFIG. 10D illustrate exemplary MALDI-TOF spectra of isolated fractions S1, S2, S3 and S4 fromFIG. 9 . -
FIG. 11 illustrates the results from an analysis of immunoassay performance using native TPO and recombinant TPO (“rTPO”). -
FIG. 12A ,FIG. 12B ,FIG. 12C , andFIG. 12D illustrate the results from exemplary experiments performed using the disclosed immunoassays:FIG. 12A ) antigen bridge,FIG. 12B ) IgG class capture,FIG. 12C ) rTPO capture, andFIG. 12D ) competition/inhibition formats. Each assay was performed using the ADVIA CENTAUR® system. RLU output associated with standardization material value was assigned fromWHO 66/387 Human Anti-thyroid Microsome Serum. - The disclosed methods and kits may be understood more readily by reference to the following detailed description taken in connection with the accompanying figures, which form a part of this disclosure. It is to be understood that the disclosed methods and kits are not limited to the specific methods and kits described and/or shown herein, and that the terminology used herein is for the purpose of describing particular embodiments by way of example only and is not intended to be limiting of the claimed methods and kits.
- Unless specifically stated otherwise, any description as to a possible mechanism or mode of action or reason for improvement is meant to be illustrative only, and the disclosed methods and kits are not to be constrained by the correctness or incorrectness of any such suggested mechanism or mode of action or reason for improvement.
- Throughout this text, the descriptions refer to methods of detecting an antibody and methods of diagnosing a thyroid disease. Where the disclosure describes or claims a feature or embodiment associated with a method of detecting an antibody, such a feature or embodiment is equally applicable to the methods of diagnosing a thyroid disease. Likewise, where the disclosure describes or claims a feature or embodiment associated with a method of diagnosing a thyroid disease, such a feature or embodiment is equally applicable to the methods of detecting an antibody.
- Where a range of numerical values is recited or established herein, the range includes the endpoints thereof and all the individual integers and fractions within the range, and also includes each of the narrower ranges therein formed by all the various possible combinations of those endpoints and internal integers and fractions to form subgroups of the larger group of values within the stated range to the same extent as if each of those narrower ranges was explicitly recited. Where a range of numerical values is stated herein as being greater than a stated value, the range is nevertheless finite and is bounded on its upper end by a value that is operable within the context of the invention as described herein. Where a range of numerical values is stated herein as being less than a stated value, the range is nevertheless bounded on its lower end by a non-zero value. It is not intended that the scope of the invention be limited to the specific values recited when defining a range. All ranges are inclusive and combinable.
- When values are expressed as approximations, by use of the antecedent “about,” it will be understood that the particular value forms another embodiment. Reference to a particular numerical value includes at least that particular value, unless the context clearly dictates otherwise.
- It is to be appreciated that certain features of the disclosed methods and kits which are, for clarity, described herein in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the disclosed methods and kits that are, for brevity, described in the context of a single embodiment, may also be provided separately or in any subcombination.
- As used herein, the singular forms “a,” “an,” and “the” include the plural.
- Various terms relating to aspects of the description are used throughout the specification and claims. Such terms are to be given their ordinary meaning in the art unless otherwise indicated. Other specifically defined terms are to be construed in a manner consistent with the definitions provided herein.
- The term “comprising” is intended to include examples encompassed by the terms “consisting essentially of” and “consisting of”; similarly, the term “consisting essentially of” is intended to include examples encompassed by the term “consisting of.”
- Disclosed herein are immunoassays and methods for detecting an anti-thyroid peroxidase (anti-TPO) antibody in a biological sample from a subject and/or diagnosing a thyroid disease in a subject.
- The methods of detecting an anti-thyroid peroxidase antibody in a biological sample from a subject can comprise:
-
- a) incubating the biological sample from the subject with:
- a solid support,
- an unlabeled recombinant cynomolgus monkey thyroid peroxidase (rTPO), and
- a labeled cynomolgus monkey rTPO,
- wherein, in the presence of the anti-thyroid peroxidase antibody, a complex comprising the labeled cynomolgus monkey rTPO, the unlabeled cynomolgus monkey rTPO, and the solid support is formed; and
- b) detecting the complex, the presence of which indicates the presence of the anti-thyroid peroxidase antibody in the biological sample.
- a) incubating the biological sample from the subject with:
- In some embodiments, the methods can comprise an “antigen bridge” immunoassay, an exemplary reaction scheme for which is illustrated in
FIG. 1 . A biological sample known to have, or suspected of having, ananti-TPO antibody 10, is incubated with a labeled rTPO 20 and solid support having an unlabeled rTPO bound thereto 30. In the absence of theanti-TPO antibody 10, the labeledrTPO 20 will not bind to or otherwise interact with the solid support. Thus, in the absence of the anti-TPO antibody, the labeled rTPO remains in the solution and isolation of the solid support would not result in isolation of the labeled rTPO. When theanti-TPO antibody 10 is present in the biological sample, theanti-TPO antibody 10 simultaneously binds to the unlabeled rTPO bound to thesolid support 30 and the labeledrTPO 20, thereby linking the labeled rTPO 20 and thesolid support 30 and resulting in the formation of a solid support/labeledrTPO complex 40. It is to be understood that the order in which the incubation takes place can be different from that exemplified inFIG. 1 . For example, the biological sample known to have, or suspected of having, ananti-TPO antibody 10 can first be incubated with a solid support having an unlabeled rTPO bound thereto 30 followed by incubation with a labeledrTPO 20. Alternatively, the biological sample known to have, or suspected of having, ananti-TPO antibody 10 can simultaneously be incubated with a solid support having an unlabeled rTPO bound thereto 30 and a labeledrTPO 20. - The biological sample known to have, or suspected of having, an
anti-TPO antibody 10 can be incubated in a reaction mixture for a period of time sufficient to achieve a partial reaction without allowing the reaction to achieve equilibrium, such as for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, or less than about 10 minutes. The labeledrTPO 20 can be added and incubated with the biological sample for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, or less than about 5 minutes. The solid support having unlabeled rTPO bound thereto 30 can be added to the mixture of biological sample and labeled rTPO 20 and incubated for a period of time sufficient to achieve a partial reaction without allowing the reaction to achieve equilibrium, such as for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, or about less than 10 minutes. In some embodiments, the incubating steps are performed in a total of about 10 minutes to about 20 minutes. The subsequent detecting can be performed in less than about 5 minutes. It is to be understood that the amount of time needed for the assay may vary based upon several factors including the level of the anti-TPO antibody(ies) in the biological sample and the affinity of the anti-TPO antibody(ies) for the rTPO. In some embodiments, incubating the biological sample with the reaction mixture can be performed for a period of time sufficient to enable the reaction to achieve equilibrium, such as on the order of 1 or more hours. Thus, the disclosed methods can be performed for any suitable amount of time. - The unlabeled rTPO can be directly or indirectly linked to the solid support. Suitable techniques for directly linking the unlabeled rTPO to the solid support include, for example, covalent attachment, adsorption, noncovalent interaction, or combinations thereof. In some embodiments, the unlabeled rTPO can be directly linked to the solid support by N-hydroxysuccinimide (NHS) chemistry or by 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) NHS chemistry. Suitable techniques for indirectly linking the rTPO to the solid support include, for example, linking through a peptide, a protein, an antibody, a linker, or a combination thereof. In some embodiments, the unlabeled rTPO can be indirectly linked to the solid support through streptavidin and biotin. For example, the unlabeled rTPO can be biotinylated and the solid support can comprise streptavidin.
- Exemplary solid supports include, but are not limited to, a column matrix material, a culture plate, a tube, a dish, a flask, a microtiter plate, a bead/particle, heat-killed formalin- (or other chemically)-fixed prokaryotic or eukaryotic cells, microscope slides, ACLAR® Film, or any other optically transparent polymer, or a combination thereof. The solid support can be fully or partially composed of plastic, cellulose, cellulose derivatives, nitrocellulose, glass, fiberglass, latex, or a combination thereof. In some embodiments, the solid support comprises a magnetic bead/particle. In some embodiments, the magnetic bead/particle is a paramagnetic particle (PMP). In some embodiments, the magnetic bead/particle is a latex magnetic particle (LMP).
- The label can be any suitable label known to those skilled in the art to be useful for creating a detectable signal. Suitable detectable labels include, but are not limited to, enzyme conjugates (e.g., horseradish peroxidase (HRP), alkaline phosphatase, glucose oxidase, and (3-galactosidase), fluorescent probes, radioactive isotopes, chemiluminescent compounds, bioluminescent compounds, or combination thereof. In some embodiments, the label is an acridinium ester (“AE”) or an analog thereof. Suitable AE analogs include: dimethyl acridinium ester (DMAE), N-sulfopropyl dimethyl acridinium ester (NSP-DMAE), high quantum yield acridinium ester (HQYAE, acridinium, 9-[[4-[[[6-[(2,5-dioxo-1-pyrrolidinyl)oxy]-6-oxohexyl]amino]carbonyl]-2,6-dimethylphenoxy]carbonyl]-2,7-bis(3,6,9,12,15,18-hexaoxanonadec-1-yloxy)-10-(3-sulfopropyl)-, inner salt), Zwitterionic acridinium ester (ZAE, Acridinium, 9-[[4-[[[3-[[3-[[5-[(2,5-dioxo-1-pyrrolidinyl)oxy]-1,5-dioxopentyl]amino]propyl]methyl(3-sulfopropyl)ammonio]propyl]amino]carbonyl]-2,6-dimethylphenoxy]carbonyl]-10-(3-sulfopropyl)-, bis(inner salt)), N-sulfopropyl-2-isopropoxy dimethyl acridinium ester (Iso-Di-ZAE), trisulfopropyl acridinium ester (TSP-AE), or N-sulfopropyl dimethyl acridinium ester with hexa(ethylene)glycol linker (HEG-GLU-AE). In some embodiments, the labeled cynomolgus monkey rTPO comprises rTPO-NSP-DMAE. The rTPO-NSP-DMAE can be present at about 50 ng/ml to about 2 μg/ml. In some embodiments, the rTPO-NSP-DMAE can be present at about 220 ng/ml.
- The solid support having unlabeled rTPO bound thereto and/or the labeled rTPO can be present in a buffer comprising, for example, phosphate buffer, NaCl, EDTA, pluronic F-127, sodium azide, sorbitol, sulfhydryl modified bovine serum, or any combinations, variations, or equivalents thereof. In one embodiment, the buffer comprises about 100 mM phosphate buffer, about 400 mM NaCl, about 1.9 g/L EDTA, about 0.2% (v/v) pluronic F-127, about 0.9 g/L sodium azide, about 10% sorbitol, and about 10 g/L sulfhydryl modified bovine serum albumin.
- Also provided are methods of detecting an anti-thyroid peroxidase antibody in a biological sample from a subject comprising:
-
- a) incubating the biological sample from the subject with:
- a solid support,
- a cynomolgus monkey rTPO, and
- an anti-human secondary antibody,
- wherein, in the presence of the anti-thyroid peroxidase antibody, a complex comprising the solid support, the cynomolgus monkey rTPO, and the anti-human secondary antibody is formed; and
- b) detecting the complex, the presence of which indicates the presence of the anti-thyroid peroxidase antibody in the biological sample.
- a) incubating the biological sample from the subject with:
- The anti-human secondary antibody can be directly or indirectly linked to the solid support and the cynomolgus monkey rTPO can comprise a label. In some embodiments, the anti-human secondary antibody can be directly linked to the solid support by glutaraldehyde fixation.
- In some embodiments, the methods can comprise an “IgG class capture” immunoassay, an exemplary reaction scheme for which is illustrated in
FIG. 2 . A biological sample known to have, or suspected of having, ananti-TPO antibody 10, is incubated with a labeled rTPO 20 and a solid support having an unlabeled anti-human secondary antibody bound thereto 50. In the absence of theanti-TPO antibody 10, the labeledrTPO 20 will not bind to or otherwise interact with the solid support. Thus, in the absence of the anti-TPO antibody, the labeled rTPO remains in the solution and isolation of the solid support would not result in isolation of the labeled rTPO. When theanti-TPO antibody 10 is present in the biological sample, theanti-TPO antibody 10 simultaneously binds to the unlabeled anti-human secondary antibody bound to thesolid support 50 and the labeledrTPO 20, thereby linking the labeled rTPO 20 and thesolid support 50 and resulting in the formation of a solid support/labeledrTPO complex 60. It is to be understood that the order in which the incubation takes place can be different from that exemplified inFIG. 2 . For example, the biological sample known to have, or suspected of having, ananti-TPO antibody 10 can first be incubated with a solid support having an unlabeled anti-human secondary antibody bound thereto 50 followed by incubation with a labeledrTPO 20. Alternatively, the biological sample known to have, or suspected of having, ananti-TPO antibody 10 can simultaneously be incubated with a solid support having an unlabeled anti-human secondary antibody bound thereto 50 and a labeledrTPO 20. - The biological sample known to have, or suspected of having, an
anti-TPO antibody 10 can be incubated in a reaction mixture for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, or less than about 10 minutes. The labeledrTPO 20 can be added and incubated with the biological sample for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, or less than about 5 minutes. The solid support having an unlabeled anti-human secondary antibody bound thereto 50 can be added to the mixture of biological sample and labeled rTPO 20 and incubated for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, or about less than 10 minutes. In some embodiments, the incubating steps are performed in a total of about 10 minutes to about 20 minutes. The subsequent detecting can be performed in less than about 5 minutes. It is to be understood that the amount of time needed for the assay may vary based upon several factors including the level of the anti-TPO antibody(ies) in the biological sample and the affinity of the anti-TPO antibody(ies) for the rTPO. Thus, the disclosed methods can be performed for any suitable amount of time. - The cynomolgus monkey rTPO can be directly or indirectly linked to the solid support and the anti-human secondary antibody can comprise a label. In some embodiments, the rTPO can be directly linked to the solid support by N-hydroxysuccinimide (NHS) chemistry or by 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) NHS chemistry.
- In some embodiments, the methods can comprise an “rTPO capture” immunoassay, an exemplary reaction scheme for which is illustrated in
FIG. 3 . A biological sample known to have, or suspected of having, ananti-TPO antibody 10, is incubated with a labeled anti-humansecondary antibody 70 and a solid support having an unlabeled rTPO bound thereto 30. In the absence of theanti-TPO antibody 10, the labeled anti-humansecondary antibody 70 will not bind to or otherwise interact with the solid support. Thus, in the absence of the anti-TPO antibody, the labeled anti-human secondary antibody remains in the solution and isolation of the solid support would not result in isolation of the labeled anti-human secondary antibody. When theanti-TPO antibody 10 is present in the biological sample, theanti-TPO antibody 10 simultaneously binds to the unlabeled rTPO bound to thesolid support 30 and the labeled anti-humansecondary antibody 70, thereby linking the labeled anti-humansecondary antibody 70 and thesolid support 30 and resulting in the formation of a solid support/labeled anti-humansecondary antibody complex 80. It is to be understood that the order in which the incubation takes place can be different from that exemplified inFIG. 3 . For example, the biological sample known to have, or suspected of having, ananti-TPO antibody 10 can first be incubated with a solid support having an unlabeled rTPO bound thereto 30 followed by incubation with a labeled anti-humansecondary antibody 70. Alternatively, the biological sample known to have, or suspected of having, ananti-TPO antibody 10 can simultaneously be incubated with a solid support having an unlabeled rTPO bound thereto 30 and a labeled anti-humansecondary antibody 70. - The biological sample known to have, or suspected of having, an
anti-TPO antibody 10 can be incubated in a reaction mixture for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, or less than about 10 minutes. The labeled anti-humansecondary antibody 70 can be added and incubated with the biological sample for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, or less than about 5 minutes. The solid support having an unlabeled rTPO bound thereto 30 can be added to the mixture of biological sample and labeled anti-humansecondary antibody 70 and incubated for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, about 6 minutes, about 7 minutes, or about less than 10 minutes. In some embodiments, the incubating steps are performed in a total of about 10 minutes to about 20 minutes. The subsequent detecting can be performed in less than about 5 minutes. It is to be understood that the amount of time needed for the assay may vary based upon several factors including the level of the anti-TPO antibody(ies) in the biological sample and the affinity of the anti-TPO antibody(ies) for the rTPO. Thus, the disclosed methods can be performed for any suitable amount of time. - The anti-human secondary antibody or the cynomolgus monkey rTPO can be directly or indirectly linked to the solid support by any suitable means known to those skilled in the art. Suitable techniques for direct linking include, for example, covalent attachment, adsorption, noncovalent interaction, or combinations thereof. In some embodiments, the anti-human secondary can be directly linked to the solid support by glutaraldehyde fixation. Suitable means for indirect linking include, for example, linking through a peptide, a protein, an antibody, a linker, or a combination thereof. In some embodiments, the anti-human secondary antibody or the cynomolgus monkey rTPO can be indirectly linked to the solid support through streptavidin and biotin. For example, the unlabeled anti-human secondary antibody or the unlabeled rTPO can be biotinylated and the solid support can comprise streptavidin.
- Exemplary solid supports include, but are not limited to, a column matrix material, a culture plate, a tube, a dish, a flask, a microtiter plate, a bead/particle, heat-killed formalin- (or other chemically)-fixed prokaryotic or eukaryotic cells, microscope slides, ACLAR® Film, or any other optically transparent polymer, or a combination thereof. The solid support can be fully or partially composed of plastic, cellulose, cellulose derivatives, nitrocellulose, glass, fiberglass, latex, or a combination thereof. In some embodiments, the solid support comprises a magnetic bead/particle. In some embodiments, the magnetic bead/particle is a paramagnetic particle (PMP). In some embodiments, the magnetic bead/particle is a latex magnetic particle (LMP).
- The anti-human secondary antibody can be an IgA, IgD, IgG, IgE, or IgM isotype or a single domain format, such as a single-domain antibody from camelid. In some embodiments, the anti-human secondary antibody is an anti-human IgG. In some embodiments, the anti-human secondary antibody is a commercially available anti-human secondary antibody. Aptamers that are specific for the anti-TPO antibody can also be used.
- The label can be any suitable label known to those skilled in the art to be useful for creating a detectable signal. Suitable detectable labels include, but are not limited to, enzyme conjugates (e.g., horseradish peroxidase (HRP), alkaline phosphatase, glucose oxidase, and (3-galactosidase), fluorescent probes, radioactive isotopes, chemiluminescent compounds, bioluminescent compounds, or a combination thereof. In some embodiments, the label can be an AE or an analog thereof. Suitable AE analogs include: dimethyl acridinium ester (DMAE), N-sulfopropyl dimethyl acridinium ester (NSP-DMAE), high quantum yield acridinium ester (HQYAE), Zwitterionic acridinium ester (ZAE), N-sulfopropyl-2-isopropoxy dimethyl acridinium ester (Iso-Di-ZAE), trisulfopropyl acridinium ester (TSP-AE), or N-sulfopropyl dimethyl acridinium ester with hexa(ethylene)glycol linker (HEG-GLU-AE). In some embodiments, the labeled cynomolgus monkey rTPO comprises rTPO-NSP-DMAE. The rTPO-NSP-DMAE can be present at about 50 ng/ml to about 2 μg/ml. In some embodiments, the rTPO-NSP-DMAE can be present at about 220 ng/ml.
- The solid support having unlabeled anti-human secondary antibody or unlabeled rTPO bound thereto and/or the labeled rTPO or labeled anti-human secondary antibody can be present in a buffer comprising, for example, phosphate buffer, NaCl, EDTA, pluronic F-127, sodium azide, sorbitol, sulfhydryl modified bovine serum, or any combinations, variations, or equivalents thereof. In one embodiment, the buffer comprises about 100 mM phosphate buffer, about 400 mM NaCl, about 1.9 g/L EDTA, about 0.2% (v/v) pluronic F-127, about 0.9 g/L sodium azide, about 10% sorbitol, and about 10 g/L sulfhydryl modified bovine serum albumin.
- Also provided are methods of detecting an anti-thyroid peroxidase antibody in a biological sample from a subject comprising:
-
- a) incubating the biological sample from the subject with a solid support, an unlabeled anti-TPO antibody, a cynomolgus monkey rTPO, and a labeled anti-TPO antibody; and
- b) detecting the anti-thyroid peroxidase antibody in the biological sample, the detecting comprising analyzing a decrease in the formation of a complex comprising the solid support, the unlabeled anti-TPO antibody, the cynomolgus monkey rTPO, and the labeled anti-TPO antibody.
- Analyzing a decrease in the formation of the complex can be performed, for example, by comparing a read-out of a signal from the labeled anti-TPO antibody in a reaction mixture with the biological sample to a read-out of a signal from the labeled anti-TPO antibody in a reaction mixture without the biological sample. If the read-out of the signal from the reaction mixture with the biological sample is less than the read-out from the reaction mixture without the biological sample, formation of the complex is decreased. The amount of complex formed is inversely proportional to the presence of the anti-thyroid peroxidase antibody in the biological sample.
- In some embodiments, the methods can comprise a “competition” immunoassay or an “inhibition” immunoassay, an exemplary reaction scheme for which is illustrated in
FIG. 4 . As used herein, a “competition” immunoassay refers to an immunoassay in which two or more binding molecules compete for binding to a target molecule. The binding molecules can be antibodies, for example, and the target molecule can be an antigen. The binding molecules can compete, for example, for binding to the same epitope(s) on the antigen. An “inhibition” immunoassay refers to an immunoassay in which one or more binding molecules inhibit binding of one or more other binding molecules to a target molecule. The binding molecules can be antibodies, for example, and the target molecule can be an antigen. Inhibition can be caused by steric hindrance or other known mechanisms of binding inhibition. Whether the claimed assays are classified as a “competition” or “inhibition” immunoassay will depend, for example, on the rTPO epitope recognized by the anti-thyroid peroxidase antibody in the biological sample and the labeled anti-TPO antibody. The claimed methods encompass both competition and inhibition immunoassays, and thus the terms “competition” and “inhibition” are not intended to limit the scope of the claimed methods. - In some embodiments of the competition/inhibition immunoassay, the labeled anti-TPO antibody and the rTPO can be in pre-formed immune complex prior to their addition to the reaction mixture. In some embodiments, the unlabeled anti-TPO antibody and solid support can be in pre-formed complex prior to their addition to the reaction mixture. In some embodiments, the labeled anti-TPO antibody, the rTPO, the unlabeled anti-TPO antibody, and the solid support are not in a pre-formed complex prior to their addition to the reaction mixture. In yet other embodiments, the labeled anti-TPO antibody, the rTPO, the unlabeled anti-TPO antibody, and the solid support are all present in a pre-formed complex prior to their addition to the reaction mixture. Whether the various components are in one or more pre-formed complexes prior to their addition to the reaction mixture will depend, in part, on the dissociation constants (KD) of the labeled and unlabeled antibodies and the rTPO. The disclosed methods are not limited by the type or extent of complex formation added to the reaction mixture. It is to be understood that the biological sample, the labeled anti-TPO antibody, the rTPO, the unlabeled anti-TPO antibody, and the solid support can be added to the reaction mixture in any order.
-
FIG. 4 discloses one exemplary embodiment of the competition/inhibition immunoassays described herein, in which a labeledanti-TPO antibody 110 and anrTPO 120 are incubated with a solid support having an unlabeled anti-TPO antibody bound thereto 130. In the absence of the anti-TPO antibody from thebiological sample 10, the labeledanti-TPO antibody 110 will bind to therTPO 120 and in turn bind to or interact with the solid support having unlabeled anti-TPO antibody bound thereto 130, thereby forming a complex 140 comprising the labeledanti-TPO antibody 110, therTPO 120, and the solid support. Thus, in the absence of the anti-TPO antibody from thebiological sample 10, the labeledanti-TPO antibody 110 will be coupled to the solid support, isolation of which will result in isolation of the labeledanti-TPO antibody 110. When theanti-TPO antibody 10 is present in the biological sample, theanti-TPO antibody 10 will compete with or otherwise inhibit the labeledanti-TPO antibody 110 for binding to therTPO 120 or will compete with or otherwise inhibit the unlabeled anti-TPO antibody bound to thesolid support 130 for binding to therTPO 120, thereby preventing the complex from forming or displacing the labeled anti-TPO antibody from the complex 140. Thus, in the presence of anti-TPO antibody from thebiological sample 10, the presence of complex 140 comprising the labeledanti-TPO antibody 110, therTPO 120, and the solid support is decreased. - The labeled
anti-TPO antibody 110, theunlabeled rTPO 120, and the unlabeled anti-TPO antibody bound to thesolid support 130 can be incubated in a reaction mixture for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, or less than about 10 minutes. The biological sample known to have, or suspected of having, ananti-TPO antibody 10 can be added and incubated in the reaction mixture for about 1 minute, about 2 minutes, about 3 minutes, about 4 minutes, about 5 minutes, or less than about 10 minutes. In some embodiments, the incubating steps are performed in a total of about 10 minutes to about 20 minutes. The subsequent detecting can be performed in less than about 5 minutes. It is to be understood that the amount of time needed for the assay may vary based upon several factors including the level of the anti-TPO antibody(ies) in the biological sample and the affinity of the anti-TPO antibody(ies) for the rTPO. Thus, the disclosed methods can be performed for any suitable amount of time. - The unlabeled anti-TPO antibody can be directly or indirectly coupled to the solid support. Suitable techniques for directly coupling the unlabeled anti-TPO antibody to the solid support include, for example, covalent attachment, adsorption, noncovalent interaction, or combinations thereof. Suitable means for indirectly coupling the unlabeled anti-TPO antibody to the solid support include, for example, linking through a peptide, a protein, an antibody, a linker, or a combination thereof. In some embodiments, the unlabeled anti-TPO antibody can be indirectly coupled to the solid support through streptavidin and biotin. For example, the unlabeled anti-TPO antibody can be biotinylated and the solid support can comprise streptavidin. The labeled and/or the unlabeled anti-TPO antibody can be any known commercially available anti-TPO antibody.
- Exemplary solid supports include, but are not limited to, a column matrix material, a culture plate, a tube, a dish, a flask, a microtiter plate, a bead/particle, heat-killed formalin- (or other chemically)-fixed prokaryotic or eukaryotic cells, microscope slides, ACLAR® Film, or any other optically transparent polymer, or a combination thereof. The solid support can be fully or partially composed of plastic, cellulose, cellulose derivatives, nitrocellulose, glass, fiberglass, latex, or a combination thereof. In some embodiments, the solid support comprises a magnetic bead/particle. In some embodiments, the magnetic bead/particle is a paramagnetic particle (PMP). In some embodiments, the magnetic bead/particle is a latex magnetic particle (LMP).
- The label can be any suitable label known to those skilled in the art to be useful for creating a detectable signal. Suitable detectable labels include, but are not limited to, enzyme conjugates (e.g., horseradish peroxidase (HRP), alkaline phosphatase, glucose oxidase, and (3-galactosidase), fluorescent probes, radioactive isotopes, chemiluminescent compounds, bioluminescent compounds, or combination thereof. In some embodiments, the label is an AE or an analog thereof. Suitable AE analogs include: dimethyl acridinium ester (DMAE), N-sulfopropyl dimethyl acridinium ester (NSP-DMAE), high quantum yield acridinium ester (HQYAE), Zwitterionic acridinium ester (ZAE), N-sulfopropyl-2-isopropoxy dimethyl acridinium ester (Iso-Di-ZAE), trisulfopropyl acridinium ester (TSP-AE), or N-sulfopropyl dimethyl acridinium ester with hexa(ethylene)glycol linker (HEG-GLU-AE). In some embodiments, the labeled anti-TPO antibody is anti-TPO IgG HEG-GLU-AE. The anti-rTPO IgG HEG-GLU-AE can be present at about 50 ng/ml to about 2 μg/ml. In some embodiments, the anti-rTPO IgG HEG-GLU-AE can be present at about 420 ng/ml.
- The solid support having unlabeled anti-TPO antibody bound thereto and/or the unlabeled rTPO and/or the labeled anti-TPO antibody can be present in a buffer comprising, for example, phosphate buffer, NaCl, EDTA, pluronic F-127, sodium azide, sorbitol, sulfhydryl modified bovine serum, or any combinations, variations, or equivalents thereof. In one embodiment, the buffer comprises about 100 mM phosphate buffer, about 400 mM NaCl, about 1.9 g/L EDTA, about 0.2% (v/v) pluronic F-127, about 0.9 g/L sodium azide, about 10% sorbitol, and about 10 g/L sulfhydryl modified bovine serum albumin.
- Further disclosed are methods of diagnosing a thyroid disease in a subject, the methods comprising incubating a biological sample from the subject with a solid support, an unlabeled recombinant cynomolgus monkey thyroid peroxidase (rTPO), and a labeled cynomolgus monkey rTPO. In the presence of an anti-thyroid peroxidase antibody in the biological sample, a complex comprising the labeled cynomolgus monkey rTPO, the unlabeled cynomolgus monkey rTPO, and the solid support is formed. The method further comprises diagnosing the subject with the thyroid disease if the complex is formed.
- Methods of diagnosing a thyroid disease in a subject comprising incubating a biological sample from the subject with a solid support, a cynomolgus monkey rTPO, and an anti-human secondary antibody are also provided. In the presence of an anti-thyroid peroxidase antibody in the biological sample, a complex comprising the solid support, the cynomolgus monkey rTPO, and the anti-human secondary antibody is formed. The method further comprises diagnosing the subject with the thyroid disease if the complex is formed.
- Also disclosed are methods of diagnosing a thyroid disease in a subject, the methods comprising incubating a biological sample from a subject with a solid support, an unlabeled anti-TPO antibody, a cynomolgus monkey TPO, and a labeled anti-TPO antibody, and diagnosing the thyroid disease if the formation of a complex comprising the solid support, the unlabeled anti-TPO antibody, the cynomolgus monkey rTPO, and the labeled anti-TPO antibody is decreased. The presence of an anti-thyroid peroxidase antibody in the biological sample decreases formation of a complex comprising the solid support, the unlabeled anti-TPO antibody, the cynomolgus monkey rTPO, and the labeled anti-TPO antibody. The labeled and/or the unlabeled anti-TPO antibody can be any known or commercially available anti-TPO antibody.
- The methods of diagnosing can further comprise a step of detecting the complex. For example, detecting the complex may comprise taking a read-out of a signal from the label, wherein the intensity of the signal from the label indicates the amount of label present in the assay.
- The thyroid disease can be an autoimmune disorder. In some embodiments, the autoimmune disorder is Hashimoto's thyroiditis or Graves' disease.
- Similar to the methods of detecting described above, in the methods of diagnosing, the unlabeled rTPO, the unlabeled anti-human secondary antibody, or the unlabeled anti-TPO antibody can be directly or indirectly linked/coupled to the solid support. Suitable techniques for direct linking/coupling include, for example, covalent attachment, adsorption, noncovalent interaction, or combinations thereof. In some embodiments, the direct linking/coupling can be achieved by glutaraldehyde fixation, N-hydroxysuccinimide (NHS) chemistry, or 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) NHS chemistry. Suitable means for indirect linking/coupling include, for example, linking/coupling through a peptide, a protein, an antibody, a linker, or a combination thereof. In some embodiments, the indirect linking/coupling to the solid support is via streptavidin and biotin. For example, the unlabeled rTPO, the unlabeled anti-human secondary antibody, or the unlabeled anti-TPO antibody can be biotinylated and the solid support can comprise streptavidin.
- Exemplary solid supports include, but are not limited to, a column matrix material, a culture plate, a tube, a dish, a flask, a microtiter plate, a bead/particle, heat-killed formalin- (or other chemically)-fixed prokaryotic or eukaryotic cells, microscope slides, ACLAR® Film, or any other optically transparent polymer, or a combination thereof. The solid support can be fully or partially composed of plastic, cellulose, cellulose derivatives, nitrocellulose, glass, fiberglass, latex, or a combination thereof. In some embodiments, the solid support comprises a magnetic bead/particle. In some embodiments, the magnetic bead/particle is a paramagnetic particle (PMP). In some embodiments, the magnetic bead/particle is a latex magnetic particle (LMP).
- The label can be any suitable label known to those skilled in the art to be useful for creating a detectable signal. Suitable detectable labels include, but are not limited to, enzyme conjugates (e.g., horseradish peroxidase (HRP), alkaline phosphatase, glucose oxidase, and β-galactosidase), fluorescent probes, radioactive isotopes, chemiluminescent compounds, bioluminescent compounds, or combination thereof. In some embodiments, the label is an AE or an analog thereof. Suitable AE analogs include: dimethyl acridinium ester (DMAE), N-sulfopropyl dimethyl acridinium ester (NSP-DMAE), high quantum yield acridinium ester (HQYAE), Zwitterionic acridinium ester (ZAE), N-sulfopropyl-2-isopropoxy dimethyl acridinium ester (Iso-Di-ZAE), trisulfopropyl acridinium ester (TSP-AE), or N-sulfopropyl dimethyl acridinium ester with hexa(ethylene)glycol linker (HEG-GLU-AE). In some embodiments, the labeled cynomolgus monkey rTPO comprises rTPO-NSP-DMAE. The rTPO-NSP-DMAE can be present at about 50 ng/ml to about 2 μg/ml. In some embodiments, the rTPO-NSP-DMAE can be present at about 220 ng/ml. In some embodiments, the labeled anti-TPO antibody is anti-rTPO IgG HEG-GLU-AE. The anti-rTPO IgG HEG-GLU-AE can be present at about 50 ng/ml to about 2 μg/ml. In some embodiments, the anti-rTPO IgG HEG-GLU-AE can be present at about 420 ng/ml.
- Suitable times for performing the methods of diagnosing an autoimmune disease include those provided above for the various methods of detecting an antibody.
- The methods can further comprise determining a level of the anti-thyroid peroxidase antibody in the biological sample of the subject. In some embodiments, the level of the anti-thyroid peroxidase antibody in the biological sample of the subject is directly proportional to the level of the complex detected. Thus, the level of anti-TPO antibody can be determined by determining the level of solid support coupled to or in complex with the labeled component (i.e. the labeled rTPO or antibody). Determining the level of solid support coupled to or in complex with the labeled component can be performed, for example, by measuring the signal from the complex. Similarly, in embodiments wherein the method is used to diagnose a thyroid disease in a subject, the solid support coupled to or in complex with the labeled component is detected by measuring the signal or absence thereof from the labeled component linked to the solid support.
- The disclosed methods can be performed manually or can be automated. For example, the disclosed methods can be performed using an ADVIA CENTAUR® Immunoassay System or an ATELLICA™ system.
- In some embodiments, the anti-TPO antibody is a patient anti-TPO antibody. In some embodiments, the anti-TPO antibody is an autoantibody.
- Suitable biological samples for detecting the anti-TPO antibody include any biological sample from a subject that contains, or is suspected of containing, the anti-TPO antibody including, but not limited to, serum, plasma, whole blood, saliva, urine, semen, perspiration, tears, and body tissues.
- The immunoassays disclosed herein employ a recombinant thyroid peroxidase (rTPO). In some embodiments, the rTPO is from cynomolgus monkey. In some embodiments, the rTPO comprises the amino acid sequence set forth in SEQ ID NO: 1 (Table 1). In some embodiments, the rTPO further comprises an epitope tag. The epitope tag can be at the N-terminus or at the C-terminus of the rTPO. The epitope tag can be any suitable tag known to persons skilled in the art including, but not limited to, a 6-histidine tag, a hemagglutinin tag, a glutathione-S-transferase, a maltose binding protein, or a chitin binding protein. In some embodiments, the rTPO comprises a C-terminal 6-histidine tag.
-
TABLE 1 Macaca fascicularis rTPO amino acid sequence (SEQ ID NO: 1) SEQ ID NO: 1 ADPGYLLECT EAFFPFISRG KELLWGKPEE SRVAGILEES KRLVDTAMYA TMQRNLKKRE ILSPHQLLSF SKLPEPTSGE IARAAEIMET SIQAMKRKVN LKIQQSQHPT DALSEDLLSI IANMSGCLPY MLPPKCPNTC LANKYRPITG ACNNRDHPRW GASNTALARW LPPVYEDGES QPRGWNPSIL HNGFPLPPVR EVTRHVIQVS NEVVTDDDRY SDLLMAWGQY IDHDIAFTPQ STSKAAFRGG ADCQVTCENQ NPCFPIQLPE EARPAAGTAC LPFYRSSAAC GTGDQGALFG NLSTANPRQQ MNGLTSFLDA STVYGSSPAL ERQLRNWTSA EGLLRVHARL RDSGRAYLPF APPRAPAACA PEPGIPGETR GPCFLAGDGR ASEVPSLTAL HTLWLREHNR LAAALKALNA HWSADAVYQE ARKVVGALHQ IITLRDYVPR ILGPEAFQQY VGPYEGYDSA ANPTVSNVES TAAFRFGHAT IHPLVRRLDA GFQEHPGLPG LWLHETFFSP WTLLHGGGLD PLIRGLLARP AKLQVQDQLM NEELTERLFV LSNSSTLDLA SINLQRGRDH GLPGYNEWRE FCGLPRLETP ADLSTAIASR SVADKILDLY KHPDNIDVWL GGLAENFLPR ARTGPLFACL IGKQMKALRD GDWFWWENSH VFTDAQRHEL EKHSLSRVIC DNTGLTRVPV DAFRVGKFPE DFESCDSIPG MNLEAWRETF PQDDKCGFPE SVENGDFVHC EESGRRVLVY SCRHGYELQG HEQLTCTQEG WDFQPPLCKD VNECADGAHP PCHASARCRN TKGGFQCLCA DPYELGDDGR TCVDSGRLPR - Further disclosed herein are kits. In some embodiments, the kits can comprise a solid support, an unlabeled cynomolgus monkey rTPO, and a labeled cynomolgus monkey rTPO.
- The kits can comprise a solid support, a cynomolgus monkey rTPO, and an anti-human secondary antibody. In some embodiments, the cynomolgus monkey rTPO comprises a label or the anti-human secondary antibody comprises a label.
- The kits can comprise a solid support, a cynomolgus monkey TPO and an anti-TPO antibody. In some embodiments, a portion of the anti-TPO antibodies are unlabeled and a portion of the anti-TPO antibodies are labeled.
- Suitable solid supports and labels for any of the kits disclosed herein include those solid supports and labels disclosed for the methods above.
- The following examples are provided to further describe some of the embodiments disclosed herein. The examples are intended to illustrate, not to limit, the disclosed embodiments.
- rTPO Cloning
- Monkey thyroid tissue was obtained from cynomolgus monkey and mRNA was isolated and purified using Trizol/Chloroform extraction (Invitrogen, catalogue #15596026). A cDNA library was prepared using Invitrogen Thermo-Script RT-PCR kit.
- Using PCR, a soluble form of TPO was amplified from the cDNA library and the PCR product was purified using a Qiagen PCR purification kit (QIAquick PCR Purification Kit, catalogue #28104). The purified PCR product was digested with XbaI (New England Biolabs cat #R0145S) and NotI (New England Biolabs cat #R0189S) restriction endonucleases and gel-extracted. The gel-extracted TPO was ligated into a baculovirus expression vector. The vector was transformed in competent cells and plated on ampicillin-selected plates.
- Resulting colonies were PCR-screened and positive clones were grown for plasmid generation and purification. Several plasmid clones were sequenced using a Beckman CEQ 8000 sequencer; clones containing TPO were verified. All PCR and sequencing primers were synthesized using an ABI Expedite 8909 DNA Synthesizer. The cDNA encodes a cynomolgus monkey rTPO having the amino acid sequence of SEQ ID NO. 1 (Table 1).
- Transient Transfection to Yield rTPO Baculoviruses
- Baculoviral DNA was combined with a transfer plasmid comprising the rTPO sequence and incubated with Grace's media and transfection reagent (Invitrogen, Bac-N-Blue Transfection Kit, catalogue #K855-01). After transfection of Spodoptra frugiperda (Sf) cells, cell culture supernatants were subsequently screened for recombinant viruses and selected recombinants were purified, amplified and sequenced to confirm the identity of rTPO.
- rTPO Purification
- Purified recombinant baculovirus containing the rTPO was used to infect cultures of Trichoplusia ni PRO (Tni PRO) in ESF921 cell culture medium. Transduced rTPO was secreted into the cell culture supernatant.
- rTPO was isolated from the supernatant using Chelating Sepharose Fast Flow immobilized metal (Nickel) affinity chromatography followed by size exclusion chromatography. Briefly, the chelating sepharose gel (GE Healthcare Catalog No. 17-0575-01) was charged with 100 mM NiSO4. rTPO in the culture supernatant was allowed to bind to the gel for 1.5 hours. Non-specific proteins were removed by washing the gel with 0.5 M Sodium Chloride, 0.05 M Tris pH 8.0, 10 mM Imidazole. rTPO was then eluted with 0.5 M Sodium Chloride, 0.05 M Tris pH 8.0, 0.1 M Imidazole. The elution fraction was then subjected to S-200 size exclusion chromatography on AKTA Prime Plus liquid chromatography system, and fractions containing rTPO were pooled.
- The final pool containing pure rTPO was analyzed by SDS/PAGE, followed by Coomassie Blue staining (
FIG. 5 , panel A) or western blotting (FIG. 5 , panel B). rTPO was electrophoresed on 4-20% Tris-Glycine gels under non-reducing conditions for about 30-40 minutes at 200 V. For western blot analysis, the proteins were transferred onto nitrocellulose membrane and were probed with a mouse anti-TPO monoclonal antibody for one hour, followed by an horse radish peroxidase (HRP) conjugated, goat anti-mouse IgG polyclonal antibody (Millipore, lot 17011271) for 30 minutes; blots were developed with substrate (Surmodics BCIB) for about 5 minutes. - The extent of rTPO glycosylation was determined by ion exchange chromatography, matrix-assisted LASER desorption time-of-flight (“MALDI-TOF”) mass spectrometry, and isoelectric focusing. In each of the ion exchange chromatography, MALDI-TOF, and isoelectric focusing experiments, two protein species were identified, which appeared to be the result of glycosylation. As shown in
FIG. 6 , the major band had an average pI 6.2 and the minor band had an average pI 5.2. - To further characterize potential lot-to-lot glycan diversity in rTPO, three different lots of rTPO were each digested with one of the following enzymes: Protein Deglycosylation Mix II (including PNGase F, O-Glycosidase, α2-3,6,8,9 Neuraminidase A, β1-4 Galactosidase S, and β-N-acetylhexosaminidasef), EndoH, α2-3, 6, 8, 9 Neuraminidase, O-Glycosidase, or PNGaseF (New England Biolabs). Digested rTPO was subsequently analyzed by MALDI-TOF analysis using the Shimadzu AXIMA Confidence MALDI-TOF Mass Spectrometer. Enzyme digestion conditions for each reaction are summarized in Table 2 below. After 37° C. overnight incubation, samples were collected, cooled to room temperature, and de-salted. A 10 kDa MWCO centrifugal filter (Millipore; ref #UFC501024) was washed with 250 μl diH2O and spun for 10 minutes at 14,000 rpm. Samples were de-salted by adding digested sample to washed centrifugal filter, spinning at 14,000 rpm for 10 minutes, and decanting the flow-through. After each spin, 250 μl diH2O was aliquoted into the centrifugal filter and spun again at 14,000 rpm for 10 minutes for a total of three washes.
-
TABLE 2 Enzyme Digestion Conditions. Deglycosylation Mix EndoH Neuraminidase O-glycosidase PNGaseF Catalog# P6044S Catalog# P0702S Catalog# P0720S Catalog# P0733S Catalog# P0704S 110 μL rTPO 45 μL rTPO 20 μL rTPO 45 μL rTPO 45 μL rTPO 40 μL H2O 5 μL 10X 160 μL H2O 5 μL 10X 5 μL 10X glycosylation glycosylation glycosylation denaturation denaturation denaturation Buffer Buffer Buffer 5 μL Place mixture in 20 μL 10X Place mixture in Place mixture in Deglycosylation fully boiling H2O GlycoBuffer 1 fully boiling H2O fully boiling H2 O Mix Buffer 2 for 10 minutes for 10 minutes for 10 minutes Incubate at 75° C. 10 μL 20 μL 10 μL GlycoBuffer 10 μL for 10 minutes, cool GlycoBuffer 3Neuraminidase 2 10X GlycoBuffer 2 to RT 10X 10X Incubate at 25° C. for 15 μL EndoH 10 μL 5 μL PNGaseF 30 mins Neuraminidase 25 μL H2O 15 μL O- 35 μL H2O glycosidase 15 μL H2O All reactions were incubated overnight in a 37° C. warm water bath. - After 37° C. overnight incubation, samples were collected, cooled to room temperature, and de-salted. A 10 kDa MWCO centrifugal filter (Millipore; ref #UFC501024) was washed with 250 μL diH2O and spun for 10 minutes at 14,000 rpm. Samples were de-salted by adding digested sample to washed centrifugal filter, spinning at 14,000 rpm for 10 minutes, and decanting the flow-through. After each spin, 250 μL diH2O was aliquoted into the centrifugal filter and spun again at 14,000 rpm for 10 minutes for a total of three washes.
- All samples were desalted and reconstituted directly with a sinapinic acid (Sigma-Aldrich 49508) trifluoroacetic acid (Alfa-Aesar 44630) matrix solution. The sample to matrix ratio was optimized for each sample, with optimal ratios outlined in Table 3. A 2 μl aliquot from each sample was blotted in triplicate on the MALDI-TOF sample plate. The samples were thoroughly air dried, placed in the MALDI-TOF sample chamber, and measured on a Shimadzu Axima Confidence MALDI-TOF with laser power set at 65. The MALDI-TOF mass spectrometer was calibrated using ProteoMass Albumin Standard (Sigma; Part #A8471).
-
TABLE 3 Optimized sample-to-matrix ratios for enzyme digests. Sample Ratio (Sample-to-Matrix) De-glycosylation Mix 1:2 EndoH 1:1 Neuraminidase 1:2 O-glycosidase 1:2 PNGaseF 1:1 Undigested rTPO 1:2 - MALDI-TOF analyses of three lots of rTPO showed slight lot-to-lot differences in glycosylation (data not shown). Digestion with De-glycosylation Mix showed the most pronounced molecular weight shift; this enzyme was chosen for de-glycosylation and subsequent conjugation for functional testing on ADVIA CENTAUR® XP immunoassay (Siemens Healthcare).
- rTPO Immunoassay Characterization
- N-hydroxysuccinimide (NHS) chemistry was used to prepare native human TPO (Fitzgerald 80-1382) labeled with NSP-DMAE and recombinant cynomolgus monkey TPO labeled with NSP-DMAE. These labeled proteins were paired with biotinylated anti-human IgG coupled to streptavidin latex or para magnetic particles in 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin and tested in a 7.5 minute one-pass (time to final result (TTFR): 18 minutes) and/or 20/20 minute two-pass (TTFR: 60 minutes) formats using an ADVIA CENTAUR® system (Siemens Healthcare). In the 7.5 minute one-pass immunoassays, the sample was added at time zero. Human TPO-NSP-DMAE or rTPO-NSP-DMAE was added at 4.75 minutes, followed by reagent containing latex magnetic particles at 7.5 minutes. Magnetic separation was initiated at 13.0 minutes to isolate the latex magnetic particles. In the 20/20 two-pass immunoassays, sample was added at time zero and first-pass human TPO-NSP-DMAE or rTPO-NSP-DMAE was added at 6 minutes, followed by first-pass magnetic separation at 24.0 minutes. Second-pass human TPO-NSP-DMAE or rTPO-NSP-DMAE was added at 35.0 minutes, and second-pass magnetic separation was initiated at 52.75 minutes. In both the one-pass and two-pass formats, the magnetic particles were prepared by washing with phosphate buffered saline three times and resuspending in 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin. In the cuvette the particles were magnetically separated and resuspended in either water or tween-20 PBS according to the Centaur platform cycle parameters. Siemens aTPO Master Curve Material (Siemens 10630890) were run as samples. As shown in
FIG. 11 , recombinant TPO gave a higher signal-to-noise ratio compared to native TPO using both 7.5 minute one-pass and 20/20 minute two-pass formats on the ADVIA CENTAUR® XP. - The rTPO antigen bridge immunoassay used biotinylated rTPO directly coupled to streptavidin-coated latex magnetic particles in 0.6 mg/mL in 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin, and rTPO coupled to TSP-AE (30 ng/mL rTPO-TSP-AE in 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin). The rTPO antigen bridge format was run as a 7.5 minute one-pass (TTFR: 18 minutes) assay and required a 1:6 onboard, sample predilution. On an ADVIA CENTAUR® XP, 20 μL of diluted sample was added to a second cuvette and incubated for 4.75 minutes. 100 μL of rTPO-TSP-AE was added and incubated for 2.75 minutes. 100 μL of rTPO/latex magnetic particles was then added and incubated for 2.75 minutes. Magnetic separation was initiated at 13.0 minutes. The magnetic particles were washed with phosphate buffered saline three times, and finally resuspended to their original concentration with 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin. In the cuvette the particles were magnetically separated and resuspended in either water or tween-20 PBS according to the Centaur platform cycle parameters. An exemplary schematic of the Antigen Bridge assay format is shown in
FIG. 1 . The performance of an optimized rTPO antigen bridge immunoassay (optimized to minimize background, increase signal-to-noise and limit any prozone effect) is provided inFIG. 12A . - The human IgG class capture immunoassay used anti-human IgG monoclonal antibody directly coupled to paramagnetic particles by glutaraldehyde fixation and rTPO coupled to NSP-DMAE (0.34 mg/mL anti-human IgG/paramagnetic particles and 220 ng/mL rTPO-NSP-DMAE, both in 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin). The human IgG class capture format was run as a 7.5 minute one-pass (TTFR: 18 minutes) assay and required a 1:10 onboard, sample predilution. On an ADVIA CENTAUR® XP, 20 μL of diluted sample was added to a second cuvette and incubated for 4.75 minutes. 100 μL of rTPO-NSP-DMAE was added and incubated for 2.75 minutes. 200 μL of anti-human IgG/paramagnetic particles was added and incubated for 2.75 minutes. Magnetic particles were separated and washed as described above. An exemplary schematic of the IgG Class Capture assay format is depicted in
FIG. 2 . The performance of an optimized human IgG class capture immunoassay (optimized to minimize background, increase signal-to-noise and limit any prozone effect) is provided inFIG. 12B . - rTPO Capture Format
- The rTPO capture immunoassay used rTPO directly coupled to latex magnetic particles using 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) NHS chemistry and a monoclonal anti-human IgG antibody coupled to NSP-DMAE (0.4 mg/mL rTPO/latex magnetic particles and 1.6 μg/mL anti-human IgG antibody-NSP-DMAE, both in 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin). The rTPO capture format was run as a 7.5 minute one-pass (TTFR: 18 minutes) assay and required a 1:10 onboard, sample predilution. On an ADVIA CENTAUR® XP, 20 μL of diluted sample was added to a second cuvette. 100 μL of anti-human IgG antibody-NSP-DMAE was added and incubated for 2.75 minutes. 100 μL of rTPO/latex magnetic particles was added and incubated for 2.75 minutes. Magnetic particles were separated and washed as described above. An exemplary schematic of the rTPO Capture assay format is depicted in
FIG. 3 . The performance of an optimized rTPO capture immunoassay (optimized to minimize background, increase signal-to-noise and limit any prozone effect) is provided inFIG. 12C . - The competition/inhibition immunoassay used a biotinylated monoclonal mouse anti-rTPO IgG antibody coupled to streptavidin-coated latex magnetic particles and monoclonal mouse anti-rTPO IgG antibody coupled to HEG-GLU-AE in immune complex with unlabeled rTPO (respectively, 0.3 mg/mL mouse-anti-rTPO/latex magnetic particles and 420 ng/mL rTPO:anti-rTPO IgG HEG-GLU-AE, both in 100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, and 10 g/L sulfhydryl modified bovine serum albumin). The competition/inhibition format was run as a 7.5 minute one-pass (TTFR: 18 minutes) assay. On an ADVIA CENTAUR® XP, 20 μL of undiluted sample was added to a cuvette and incubated for 4.75 minutes. 75 μL of rTPO:anti-rTPO IgG HEG-GLU-AE and 150 μL of mouse-anti-rTPO/latex magnetic particles were added and incubated for 2.75 minutes each. Magnetic particles were separated and washed as described above. An exemplary schematic of the competition/inhibition assay format is shown in
FIG. 4 . The performance of an optimized competition/inhibition immunoassay (optimized to minimize background, increase signal-to-noise and limit any prozone effect) is provided inFIG. 12D . - Effect of rTPO Glycosylation on Immunoassay Performance
- To analyze the effect of recombinant rTPO glycosylation on immunoassy performance, immunoassays were run using the Antigen Bridge and IgG Class Capture (with labeled rTPO detection) formats. Table 4 outlines immunoassay preparation for each format. Immunoassays were run in triplicate on an ADVIA CENTAUR® XP. Samples were prepared using anti-TPO antibody-Positive Plasma spiked into PBS Buffer targeting the following doses: 0, 12.5, 25, 50, 100, 200, 300, 400, 625, 20,000 IU/mL.
- In the Antigen Bridge assay format, 30 μL of sample was added to a cuvette, followed by 180 μL diluent (100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, 10 g/L sulfhydryl modified bovine serum albumin), and the diluted sample was incubated for 4.75 minutes. 30 μL of the diluted sample was added to 100 μL diluent containing paramagnetic particles, and incubated for 2.75 minutes. 100 μL of the diluent containing labeled rTPO was added to the reaction and incubated for 6.5 minutes. The immunoassay was tested (results shown in
FIG. 7A ) with no de-glycosylation (“Control”), de-glycosylated labeled rTPO (“Glycosylated SP/Deglycosylated LR”), de-glycosylated unlabeled rTPO bound to the solid support (“Deglycosylated SP/Glycosylated LR”), and both de-glycosylated labeled rTPO and unlabeled rTPO bound to the solid support (“Deglycosylated SP & LR”). - In the IgG Class Capture assay format, 30 μL of sample was added to a cuvette, followed by 180 μL diluent (100 mM phosphate buffer, 400 mM NaCl, 1.9 g/L EDTA, 0.2% (v/v) pluronic F-127, 0.9 g/L sodium azide, 10% sorbitol, 10 g/L sulfhydryl modified bovine serum albumin), and the diluted sample was incubated for 4.75 minutes. 30 μL of the diluted sample was added to 100 μL diluent containing labeled rTPO, and incubated for 2.75 minutes. 100 μL of the diluent containing anti-human IgG Fc monoclonal antibody coupled to paramagnetic particles was added to the reaction and incubated for 6.5 minutes. The immunoassay was tested with non-deglycosylated labeled rTPO (control) and de-glycosylated labeled rTPO (
FIG. 7B ). -
TABLE 4 Solid Support (bound to [Labeled magnetic [Solid Support] rTPO] particles) (mg/mL) Labeled rTPO (ng/mL) Antigen Bridge rTPO: Sulfo- 0.6 mg/mL rTPO: NSP- 120 ng/mL NHS-LC-Biotin DMAE-Z-NHS 30X 20X IgG Class Anti-human IgG, 0.34 mg/mL rTPO: NSP- 220 ng/mL Capture w/rTPO 8D6 DMAE-Z-NHS Detection 20X - A functional assessment of rTPO, based on glycosylation, revealed that differences in rTPO glycosylation result in subtle variation in immunoreactivity (as measured by ADVIA CENTAUR® XP) against an anti-TPO antibody-positive patient pool (
FIG. 7A andFIG. 7B ). - The immunoassays demonstrated low background and a wide dynamic range for effective aTPO detection and quantification.
- rTPO Immune Complex Characterization
- FPLC size exclusion chromatography was employed to verify the in vitro formation of a recombinant TPO-anti-TPO autoantibody complex and to confirm that the anti-TPO autoantibody, rather than some other component within the patient sample, was interacting with the recombinant TPO.
- rTPOAE baseline chromatogram: rTPO labeled with N-sulfopropyl dimethyl acridinium ester (NSP-DMAE) (5 molar excess) was diluted to get ˜5 million RLU (1:600 dilution) using fractionation buffer; 50 mM Sodium Phosphate, 150 mM sodium Chloride, 0.5
% Tween 20, and 0.1% Sodium Azide at pH 7.4. This sample was analyzed by AKTA pure system withSuperdex 200 HiLoad 16/600 column using the fractionation buffer, 500 μL injection and 1 ml/minute elution; 180 fractions (1 ml each) were collected and run on Berthold AutoLumat system to generate a baseline RLU chromatogram. The labeled rTPO was represented by a single peak at MW 90-100 KDa (fractions 66-76) in the RLU chromatogram inFIG. 8 (Note: “rTPOAE” refers to rTPO labeled with an acridinium ester analog or variant, e.g., NSP-DMAE in the present example). - In vitro immune complex chromatogram: A high anti-TPO antibody patient sample pool (concentration ˜60,000 U/mL) was diluted to ˜1,500 U/mL with the fractionation buffer. One part of the diluted sample was mixed with 19 parts of the diluted (1:600) rTPO labeled with dimethyl acridinium ester (NSP-DMAE). The sample mixture was analyzed using the same column and conditions as above. The RLU chromatogram of the mixture overlaid with the baseline chromatogram in
FIG. 8 (“rTPOAE_spiker”) shows a higher molecular weight immune complex peak (fractions 45-55) along with the unbound labeled rTPO peak (Fractions 66-76). - MALDI-TOF was used to evaluate the components of the immune complex.
- Sample preparation: A high anti-TPO antibody patient pool (concentration ˜20,000 IU/mL) was diluted to ˜2,700 IU/mL with the fractionation buffer. The diluted sample was mixed with rTPO in a 1:1 ratio. The sample mixture was analyzed by AKTA Pure system with
Superdex 200 HiLoad 16/60 column and 180 (1 ml each) fractions were collected. - The A280 Chromatogram (
FIG. 9 ) shows three distinct peaks; a higher molecular weight Peak A (retention volume 52.05 mL), Peak B (retention volume 66.87 mL) and Peak C (retention volume 75.43 mL). Each of the peak area fractions were pooled separately; the higher molecular weight peak area was pooled into two samples. The pooled samples: S1 (fractions 46-49), S2 (fractions 51-54), S3 (fractions 65-68) and S4 (fractions 74-77) were concentrated using Amicon Ultra-4 Centrifugal Filters (Ultracel 30K 30,000 NMWL ref UFC803024). - MALDI-TOF procedure: Deionized water (“diH2O”) was added (500 μL) to a pre-washed Pall NanoSep filter followed by various volumes of the above S1, S2, S3, and S4 samples. The samples were then centrifuged at 12,000×g for seven minutes and washed one more time with water and reconstituted directly with a sinapinic acid (Sigma-Aldrich 49508) trifluoroacetic acid (Alfa-Aesar 44630) matrix solution to achieve 2 mg/mL protein concentration. Two microliters of each sample was directly plotted to the MALDI-TOF plate and allowed to dry. A second spotting was performed to improve sensitivity. The MALDI-TOF was calibrated using a MALDI-grade BSA standard on a Shimadzu Axima Confidence MALDI-TOF with laser power was set at 65. The MALDI-TOF result (
FIG. 10 ) showed that samples S1 and S2 primarily consisted of a ˜90 KDa protein species (rTPO) and ˜150 KDa proteins representing human TPO autoantibodies. - The results showed that the interaction between the labeled rTPO and the patient samples is specific to patient anti-TPO antibodies.
- Those skilled in the art will appreciate that numerous changes and modifications can be made to the preferred embodiments of the invention and that such changes and modifications can be made without departing from the spirit of the invention. It is, therefore, intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.
Claims (19)
1. A method of diagnosing a thyroid disease in a subject, the method comprising:
a) incubating a biological sample from the subject with:
a solid support,
an unlabeled recombinant cynomolgus monkey thyroid peroxidase (rTPO), and
a labeled cynomolgus monkey rTPO,
wherein, in the presence of an anti-thyroid peroxidase antibody in the biological sample, a complex comprising the labeled cynomolgus monkey rTPO, the unlabeled cynomolgus monkey rTPO, and the solid support is formed; and
b) diagnosing the subject with the thyroid disease if the complex is formed.
2. A method of diagnosing a thyroid disease in a subject, the method comprising:
a) incubating a biological sample from the subject with:
a solid support,
a cynomolgus monkey rTPO, and
an anti-human secondary antibody,
wherein, in the presence of an anti-thyroid peroxidase antibody in the biological sample, a complex comprising the solid support, the cynomolgus monkey rTPO, and the anti-human secondary antibody is formed; and
b) diagnosing the subject with the thyroid disease if the complex is formed.
3. A recombinantly produced thyroid peroxidase (rTPO) comprising the amino acid sequence of SEQ ID NO: 1.
4. The rTPO of claim 3 , wherein the rTPO comprises a label.
5. The rTPO of claim 4 , wherein the label comprises an enzyme conjugate, a fluorescent probe, a radioactive isotope, a chemiluminescent compound, a bioluminescent compound, or a combination thereof.
6. The rTPO of claim 5 , wherein the label comprises an acridinium ester (AE) or an analog thereof.
7. The rTPO of claim 6 , wherein the acridinium ester analog is DMAE, NSP-DMAE, HQYAE, ZAE, Iso-Di-ZAE, was TSP-AE, or HEG-GLU-AE.
8. The rTPO of claim 4 in complex with an anti-thyroid peroxidase antibody.
9. A kit comprising:
a solid support;
a cynomolgus monkey rTPO; and
an anti-human secondary antibody.
10. The kit of claim 9 , wherein the solid support comprises a column matrix material, a culture plate, a tube, a dish, a flask, a microtiter plate, a bead, or a combination thereof.
11. The kit of claim 9 , wherein:
the cynomolgus monkey rTPO comprises a label; or
the anti-human secondary antibody comprises a label.
12. The kit of claim 11 , wherein the label comprises an enzyme conjugate, a fluorescent probe, a radioactive isotope, a chemiluminescent compound, a bioluminescent compound, or a combination thereof.
13. The kit of claim 12 , wherein the label is an acridinium ester (AE) or an analog thereof.
14. A kit comprising:
a solid support;
a cynomolgus monkey rTPO; and
an anti-TPO antibody.
15. The kit of claim 14 , wherein the solid support comprises a column matrix material, a culture plate, a tube, a dish, a flask, a microtiter plate, a bead, or a combination thereof.
16. The kit of claim 14 , wherein a portion of the anti-TPO antibodies are unlabeled and a portion of the anti-TPO antibodies are labeled.
17. The kit of claim 16 , wherein the label comprises an enzyme conjugate, a fluorescent probe, a radioactive isotope, a chemiluminescent compound, a bioluminescent compound, or a combination thereof.
18. The kit of claim 17 , wherein the label is an acridinium ester (AE) or an analog thereof.
19. A kit comprising:
a solid support,
an unlabeled anti-TPO antibody,
a cynomolgus monkey rTPO,
a labeled anti-TPO antibody, and
an ADVIA Centaur© or Atellica IM© ReadyPack©.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/473,163 US20240027438A1 (en) | 2018-07-02 | 2023-09-22 | Novel thyroid peroxidase autoantibody immunoassay |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862693434P | 2018-07-02 | 2018-07-02 | |
PCT/US2019/040161 WO2020010007A1 (en) | 2018-07-02 | 2019-07-01 | Novel thyroid peroxidase autoantibody immunoassay |
US202017250182A | 2020-12-10 | 2020-12-10 | |
US17/658,119 US11835518B2 (en) | 2018-07-02 | 2022-04-06 | Thyroid peroxidase autoantibody immunoassay |
US18/473,163 US20240027438A1 (en) | 2018-07-02 | 2023-09-22 | Novel thyroid peroxidase autoantibody immunoassay |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/658,119 Continuation US11835518B2 (en) | 2018-07-02 | 2022-04-06 | Thyroid peroxidase autoantibody immunoassay |
Publications (1)
Publication Number | Publication Date |
---|---|
US20240027438A1 true US20240027438A1 (en) | 2024-01-25 |
Family
ID=69060614
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/250,182 Active US11327074B2 (en) | 2018-07-02 | 2019-07-01 | Thyroid peroxidase autoantibody immunoassay |
US17/658,119 Active 2039-09-01 US11835518B2 (en) | 2018-07-02 | 2022-04-06 | Thyroid peroxidase autoantibody immunoassay |
US18/473,163 Pending US20240027438A1 (en) | 2018-07-02 | 2023-09-22 | Novel thyroid peroxidase autoantibody immunoassay |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/250,182 Active US11327074B2 (en) | 2018-07-02 | 2019-07-01 | Thyroid peroxidase autoantibody immunoassay |
US17/658,119 Active 2039-09-01 US11835518B2 (en) | 2018-07-02 | 2022-04-06 | Thyroid peroxidase autoantibody immunoassay |
Country Status (5)
Country | Link |
---|---|
US (3) | US11327074B2 (en) |
EP (1) | EP3817761A4 (en) |
JP (1) | JP6992200B2 (en) |
CN (1) | CN112312921A (en) |
WO (1) | WO2020010007A1 (en) |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07506960A (en) * | 1991-08-28 | 1995-08-03 | ニコルス・インスティチュート・ダイアグノスティクス | Disease-associated human antibodies specific for human thyroid peroxidase |
GB2265713A (en) * | 1992-05-16 | 1993-10-06 | R S R Limited | Assay for autoantibodies against thyroglobulin or thyroid peroxidase |
US5998153A (en) * | 1992-05-19 | 1999-12-07 | The Regents Of The University Of Michigan | Thyroid peroxidase epitopic regions |
US20070178604A1 (en) * | 1999-04-30 | 2007-08-02 | Bio-Rad Laboratories, Inc. | Multi-analyte diagnostic test for thyroid disorders |
RU2239189C1 (en) * | 2003-06-05 | 2004-10-27 | Автономная некоммерческая организация "Центр иммунологии и репродукции" | Method for detecting the risk of obstetric complications |
PT2130044T (en) * | 2007-02-16 | 2017-02-03 | Genzyme Corp | Method of identifying risk for thyroid disorder |
CN101470117A (en) * | 2007-12-26 | 2009-07-01 | 天津市协和医药科技有限公司 | Chemiluminescent ligand analysis method for quantitative detection of human auto-antibody |
CN101377496A (en) * | 2008-04-16 | 2009-03-04 | 北京科美东雅生物技术有限公司 | Chemiluminescence immune analytic reagent kit for detecting thyroid peroxidase autoantibody |
RU2460072C1 (en) * | 2011-06-09 | 2012-08-27 | Вера Геннадьевна Лихванцева | Method for prediction of clinical course of endocrine ophthalmopathy in patients with graves disease by detecting anti-thyroid peroxidase antibodies |
DE18200782T1 (en) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH DISEASES IN HUMANS |
CN105087512A (en) * | 2014-05-13 | 2015-11-25 | 苏州偲聚生物材料有限公司 | Protein for detecting thyroid diseases and partial peptide of protein |
CN104237513A (en) * | 2014-09-30 | 2014-12-24 | 博奥赛斯(天津)生物科技有限公司 | Thyroid peroxidase antibody magnetic-particle chemiluminescence immune quantitative testing kit |
CN106257288A (en) * | 2016-08-15 | 2016-12-28 | 余洋 | A kind of serum T POAb IgG4 level detection method |
-
2019
- 2019-07-01 JP JP2020573295A patent/JP6992200B2/en active Active
- 2019-07-01 CN CN201980044512.9A patent/CN112312921A/en active Pending
- 2019-07-01 WO PCT/US2019/040161 patent/WO2020010007A1/en unknown
- 2019-07-01 US US17/250,182 patent/US11327074B2/en active Active
- 2019-07-01 EP EP19830829.8A patent/EP3817761A4/en active Pending
-
2022
- 2022-04-06 US US17/658,119 patent/US11835518B2/en active Active
-
2023
- 2023-09-22 US US18/473,163 patent/US20240027438A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20220236259A1 (en) | 2022-07-28 |
JP2021524589A (en) | 2021-09-13 |
EP3817761A1 (en) | 2021-05-12 |
CN112312921A (en) | 2021-02-02 |
US11327074B2 (en) | 2022-05-10 |
EP3817761A4 (en) | 2021-09-08 |
JP6992200B2 (en) | 2022-02-03 |
WO2020010007A1 (en) | 2020-01-09 |
US11835518B2 (en) | 2023-12-05 |
US20210356459A1 (en) | 2021-11-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050196818A1 (en) | Antibodies to alpha-synuclein | |
US20090042213A1 (en) | Methods and compositions for detecting thyroglobulin in a biological sample | |
US10830771B2 (en) | PIVKA-II assay method and method for manufacturing reagent or kit for PIVKA-II immunoassay | |
WO2013132347A2 (en) | Improved elisa immunoassay for calprotectin | |
US6375949B1 (en) | Monoclonal antibody recognizing serum amyloid A | |
JP5090332B2 (en) | Measurement of short chain SRL alcohol dehydrogenase (DHRS4) as a biomarker for inflammation and infection | |
WO2023103827A1 (en) | Thyroid stimulating hormone receptor antigen reagent and thyroid stimulating hormone receptor antibody quantitative test kit | |
CN112679605A (en) | Antibodies or antigen binding fragments thereof against novel coronavirus nucleocapsid proteins and uses thereof | |
JPH06502912A (en) | Analyte variant analysis | |
JP2001505999A (en) | Receptor binding assay for detecting TSH receptor autoantibodies | |
US8642347B2 (en) | Urinary CA125 peptides as biomarkers of ovarian cancer | |
JP2021529948A (en) | Direct immunoassay measurement of autoantibodies | |
EP0730155A1 (en) | Method of assaying antiphospholipid antibody and kit therefor | |
US11835518B2 (en) | Thyroid peroxidase autoantibody immunoassay | |
JPH07504896A (en) | Aminoprocollagen 1 (1) peptide | |
CN114891118B (en) | Antigen PLA2R-THSD7A-NELL-1 fusion protein, and products and uses thereof | |
Imamura et al. | Clinical application of enzyme immunoassay in the analysis of citrullinemia | |
JP3978226B2 (en) | Immunoassay to identify alcoholics and monitor alcohol consumption | |
Ropers et al. | Enzyme immunoassay for the measurement of human tenascin-C on the Bayer Immuno 1™ analyzer | |
EP4189396A1 (en) | Improved epitope for detecting and/or quantifying autoantibodies against alpha-fetoprotein | |
JPH07110879B2 (en) | Monoclonal antibody | |
US20230053846A1 (en) | Method for detecting cancer bone metastasis and detection reagent | |
Hashida et al. | Direct measurement of α‐human atrial natriuretic polypeptide in plasma by sensitive enzyme immunoassay | |
CN114910643B (en) | Method and reagent for identifying antibody combined with mutant antigen | |
WO2023013764A1 (en) | Method for estimating fibrosis progression and/or liver disease activity in non-alcoholic steatohepatitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SIEMENS HEALTHCARE DIAGNOSTICS INC., NEW YORK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHERIAN, SAJI;CORTESE, KAYLA;D'AGOSTINO, PAUL;AND OTHERS;SIGNING DATES FROM 20190930 TO 20200130;REEL/FRAME:065002/0536 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |